U.S. patent application number 15/863635 was filed with the patent office on 2018-08-23 for antisense design.
This patent application is currently assigned to Roche Innovation Center Copenhagen A/S. The applicant listed for this patent is Roche Innovation Center Copenhagen A/S. Invention is credited to Signe M. Christensen, Miriam Frieden, Henrik Frydenlund Hansen, Troels Koch, Nikolaj Dam Mikkelsen, Daniel Sejer Pedersen, Christoph Rosenbohm, Charlotte Albaek Thrue, Majken Westergaard.
Application Number | 20180237777 15/863635 |
Document ID | / |
Family ID | 32327766 |
Filed Date | 2018-08-23 |
United States Patent
Application |
20180237777 |
Kind Code |
A1 |
Christensen; Signe M. ; et
al. |
August 23, 2018 |
ANTISENSE DESIGN
Abstract
A novel class of pharmaceuticals which comprises a Locked
Nucleic Acid (LNA) which can be used in antisense therapy. These
novel oligonucleotides have improved antisense properties. The
novel oligonucleotides are composed of at least one LNA selected
from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The
oligonucleotides comprising LNA may also include DNA and/or RNA
nucleotides.
Inventors: |
Christensen; Signe M.;
(Kobenhavn, DK) ; Mikkelsen; Nikolaj Dam;
(Bronshoj, DK) ; Frieden; Miriam; (Kobenhavn,
DK) ; Hansen; Henrik Frydenlund; (Rodovre, DK)
; Koch; Troels; (Copenhagen S, DK) ; Pedersen;
Daniel Sejer; (Valby, DK) ; Rosenbohm; Christoph;
(Hoersholm, DK) ; Thrue; Charlotte Albaek;
(Hoersholm, DK) ; Westergaard; Majken; (Birkerod,
DK) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Roche Innovation Center Copenhagen A/S |
Basel |
|
CH |
|
|
Assignee: |
Roche Innovation Center Copenhagen
A/S
Basel
CH
|
Family ID: |
32327766 |
Appl. No.: |
15/863635 |
Filed: |
January 5, 2018 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14882369 |
Oct 13, 2015 |
|
|
|
15863635 |
|
|
|
|
14073722 |
Nov 6, 2013 |
|
|
|
14882369 |
|
|
|
|
13841646 |
Mar 15, 2013 |
|
|
|
14073722 |
|
|
|
|
10535472 |
Dec 19, 2005 |
9045518 |
|
|
PCT/DK2003/000788 |
Nov 18, 2003 |
|
|
|
13841646 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C12N 2310/11 20130101;
C12N 2310/344 20130101; C07H 21/02 20130101; C07H 21/04 20130101;
C12N 2310/3231 20130101; C12N 2320/30 20130101; A61K 31/7088
20130101; C12N 2310/315 20130101; C07H 19/04 20130101; C07H 19/06
20130101; C12N 2320/51 20130101; C12N 15/111 20130101; C12N 15/113
20130101; C07H 19/16 20130101; C12N 15/1137 20130101; C12N 2310/341
20130101; C07H 21/00 20130101 |
International
Class: |
C12N 15/113 20100101
C12N015/113; C07H 19/04 20060101 C07H019/04; C07H 19/06 20060101
C07H019/06; C07H 19/16 20060101 C07H019/16; C07H 21/00 20060101
C07H021/00; C07H 21/02 20060101 C07H021/02; C07H 21/04 20060101
C07H021/04; A61K 31/7088 20060101 A61K031/7088; C12N 15/11 20060101
C12N015/11 |
Foreign Application Data
Date |
Code |
Application Number |
Nov 18, 2002 |
DK |
PA2002/01774 |
Oct 20, 2003 |
DK |
PA2003/01540 |
Claims
1.-42. (canceled)
43. An oligonucleotide which comprises a sequence of nucleotides of
formula, from 5' to 3': A-B-C or A-B-C-D, wherein, A represents a
sequence of 2 to 6 locked nucleotide units (LNA); B represents a
sequence of 4 to 12 non-locked nucleotide units; C represents a
sequence of 1 to 5 locked nucleotide units; D, when present,
represents a non-locked nucleotide unit or a sequence of 1 to 3
non-locked nucleotide units; wherein region A or region C comprise
at least one amino-LNA or thio-LNA unit located adjacent to region
B.
44. The oligonucleotide according to claim 43, wherein B represents
a sequence of 2'-deoxy pentofuranose sugar moiety units.
45. The oligonucleotide according to claim 43, wherein B represents
a sequence of 6 to 12 2'-deoxy pentofuranose sugar moiety
units.
46. The oligonucleotide according to claim 45, wherein region A and
region C comprise, independently, 2 to 4 consecutive locked
nucleotide units.
47. The oligonucleotide according to claim 45, wherein both region
A and region C comprise an alpha-L-oxy-LNA nucleoside located
adjacent to region B.
48. The oligonucleotide according to claim 46, wherein both region
A and region C comprise an alpha-L-oxy-LNA nucleoside located
adjacent to region B.
49. The oligonucleotide according to claim 43, wherein the
remaining nucleosides of regions A and C are beta-D-oxy-LNA
nucleosides.
50. The oligonucleotide according to claim 45, wherein the
remaining nucleosides of regions A and C are beta-D-oxy-LNA
nucleosides.
51. The oligonucleotide according to claim 46, wherein the
remaining nucleosides of regions A and C are beta-D-oxy-LNA
nucleosides.
52. The oligonucleotide according to claim 47, wherein the
remaining nucleosides of regions A and C are beta-D-oxy-LNA
nucleosides.
53. The oligonucleotide according to claim 48, wherein the
remaining nucleosides of regions A and C are beta-D-oxy-LNA
nucleosides.
54. The oligonucleotide according to claim 43, wherein the
remaining nucleosides of regions A and C are alpha-D-oxy-LNA
nucleosides.
55. The oligonucleotide according to claim 45, wherein the
remaining nucleosides of regions A and C are alpha-D-oxy-LNA
nucleosides.
56. The oligonucleotide according to claim 46, wherein the
remaining nucleosides of regions A and C are alpha-D-oxy-LNA
nucleosides.
57. The oligonucleotide according to claim 47, wherein the
remaining nucleosides of regions A and C are alpha-D-oxy-LNA
nucleosides.
58. The oligonucleotide according to claim 48, wherein the
remaining nucleosides of regions A and C are alpha-D-oxy-LNA
nucleosides.
59. The oligonucleotide according to claim 45, wherein the region
A-B-C comprises at least one phosphorothioate internucleoside
linkages
60. The oligonucleotide according to claim 45, wherein all the
internucleoside linkages within the region A-B-C are
phosphorothioate internucleoside linkages.
Description
RELATED APPLICATIONS
[0001] This application is a continuation of U.S. Ser. No.
14/882,369, which was filed Oct. 13, 2015, which is a continuation
of U.S. Ser. No. 14/073,722, which was filed Nov. 6, 2013, which is
a continuation of U.S. Ser. No. 13/841,646, which was filed on Mar.
15, 2013, which claims priority to U.S. application Ser. No.
10/535,472, which was filed on Dec. 19, 2005, which is a National
Phase Application of PCT/DK2003/00788, which was filed Nov. 18,
2003 and Application No. PA200201774, filed Nov. 18, 2002, and
Application No. PA200301540, filed Oct. 20, 2003.
FIELD OF INVENTION
[0002] The present invention relates to pharmaceuticals comprising
antisense oligonucleotides, and novel oligonucleotides having
improved antisense properties.
BACKGROUND OF THE INVENTION
[0003] The Professors Imanishi and Wengel independently invented
Locked Nucleic Acid (LNA) in 1997 (International Patent
Applications WO 99/14226, WO 98/39352; P. Nielsen et al, J. Chem.
Soc., Perkin Trans. 1, 1997, 3423; P. Nielsen et al., Chem.
Commun., 1997, 9, 825; N. K. Christensen et al., J. Am. Chem. Soc.,
1998, 120, 5458; A. A. Koshkin et al., J. Org. Chem., 1998, 63,
2778; A. A Koshkin et al. J. Am. Chem. Soc. 1998, 120, 13252-53;
Kumar et al. Bioorg, & Med. Chem. Lett., 1998, 8, 2219-2222;
and S. Obika et al., Bioorg. Med. Chem. Lett., 1999, 515). The
first LNA monomer was based on the 2'-O--CH.sub.2-4' bicyclic
structure. Due to the configuration of this structure it is called:
beta-D-oxy-LNA. This oxy-LNA has since then showed promising
biological applications (Braasch & Corey, Biochemistry, 2002,
41(14), 4503-19; Childs et al. PNAS, 2002, 99(17), 11091-96;
Crinelli et al., Nucl. Acid. Res., 2002, 30(11), 2435-43; Elayadi
et al., Biochemistry, 2002, 41, 9973-9981; Jacobsen et al., Nucl.
Acid. Res., 2002, 30(19), in press; Kurreck et al., Nucl. Acid.
Res., 2002, 30(9), 1911-1918; Simeonov & Nikiforov, Nucl. Acid.
Res., 2002, 30(17); Alayadi & Corey, Curr. opinion in Inves.
Drugs., 2001, 2(4), 558-61; Obika et al., Bioorg. & Med. Chem.,
2001, 9, 1001-11; Braasch & Corey, Chem. & Biol., 2000, 55,
1-7; Wahlestedt et al., PNAS, 2000, 97(10), 5633-38), Freier &
Altmann, Nucl. Acid Res., 1997, 25, 4429-43; Cook, 1999,
Nucleosides & Nucleotides, 18(6&7), 1141-62.
[0004] Right after the discovery of oxy-LNA the bicyclic
furanosidic structure was chemically derivatised. Thus, the
2'-S--CH.sub.2-4' (thio-LNA) and the 2'-NH--CH.sub.2-4' (amino-LNA)
bicyclic analogues were disclosed (Singh, S. K., J. Org. Chem.,
1998, 63, 6078-79; Kumar et al. Bioorg, & Med. Chem. Lett.,
1998, 8, 2219-2222; Singh et al. J. Org. Chem., 1998, 63,
10035-39). The synthesis of the thio-LNA containing uridine as
nucleobase has been shown (Singh, S. K., J. Org. Chem., 1998, 63,
6078-79). For amino-LNA the synthesis of the thymidine nucleobase
has been disclosed (Kumar et al. Bioorg, & Med. Chem. Lett.,
1998, 8, 2219-2222; Singh et al. J. Org. Chem., 1998, 63,
10035-39). A series of LNA-diastereoisomers have been prepared
(Rajwanshi et al., J. Chem Commun. 1999; 2073-2074; Hakansson &
Wengel, Bioorg Med Chem Lett 2001; 11(7):935-938; Rajwanshi et al.,
Chem Commun., 1999; 1395-1396; Wengel at al., Nucleosides
Nucleotides Nucleic Acids, 2001; 20(4-7):389-396; Rajwanshi et al.,
Angew. Chem. Int. Ed., 2000; 39:1656-1659; Petersen et al., J.
Amer. Chem. Soc., 2001, 123(30), 7431-32; Sorensen et al., J. Amer.
Chem. Soc., 2002, 124(10), 2164-76; Vester et al., J. Amer. Chem.
Soc., 2002, 124(46), 13682-13683). In the prior art the synthesis
of alpha-L-xylo, xylo-LNA, and alpha-L-oxy-LNA containing thymidine
bases have been shown. For the alpha-L-oxy-LNA also the 5-methyl
and adenine nucleosides have been synthesised. The melting
temperature (T.sub.m) of duplexes containing the LNA
distereoisomers have been presented. It turned out that the
alpha-L-oxy-LNA has interesting properties. It was shown that the
alpha-L-oxy-LNA can be incorporated in complex chimerae comprising
DNA/RNA residues and be adapted in the oligo structure and increase
the binding. This property of being incorporated in
oligonucleotides containing several other monomeric classes and act
co-operatively is a property that the alpha-L-oxy-LNA shares with
the parent oxy-LNA. Furthermore, it has been demonstrated that a
segment of 4 consecutive alpha-L-T monomers can be incorporated in
conjunction with a segment of 4 consecutive oxy-LNA-T monomers
(Rajwanshi et al., Chem. Commun., 1999, 2073-74). Increased
stability of oligonucleotides containing alpha-L-oxy-LNA monomers
(.sup.MeC, A, T-monomers) have been demonstrated. The
alpha-L-oxy-LNA monomers were incorporated into oligonucleotides
with alternating alpha-L-oxy-LNA and DNA monomers (mix-mers) and in
fully modified alpha-L-oxy-LNA oligomers. The stability was
compared to oxy-LNA and to DNA and it was found that
alpha-L-oxy-LNA monomers displaced the same protection pattern as
oxy-LNA (Sorensen, et al., J. Amer. Chem. Soc., 2002, 124(10),
2164-76). The same alpha-L-oxy-LNA containing oligonucleotides were
tested in RNase H assays and it was found that the designs
disclosed were not efficiently recruiting RNase H. When these
examples are taken together also in combination with the data
published by Arzumanov et al (Biochemistry 2001, 40, 14645-54) it
has not been shown that alpha-L-oxy-LNA containing oligonucleotides
efficiently recruits RNase H.
[0005] Oligonucleotides containing any combination of the
diastereoisomers and any other LNA family member has not been
demonstrated.
[0006] Natural dsDNA exists at physiological pH as a B-form helix,
whereas dsRNA exists as an A-form helix. A helix formed by DNA and
RNA exists in an intermediate A/B-form. This morphological
difference is originated in the difference in the preferred sugar
conformations of the deoxyriboses and the riboses. The furanose
ring of deoxyribose exists at room temperature in an equilibrium
between C2'-endo (S-type) and C3'-endo (N-type) conformation with
an energy barrier of .about.2 kcal/mol (FIG. 3). For deoxyribose
the S-type conformation is slightly lowered in energy (.about.0.6
kcal/mol) compared to the N-type and explains why DNA is found in
the S-type conformation. The conformation leads to the B-form
helix. For ribose, and RNA, the preference is for the N-type that
leads to the A-form helix. The A-form helix is associated with
higher hybridisation stability. The oxy-LNA and the LNA analogues
are locked in the N-conformation and consequently the
oligonucleotides they are forming will be RNA-like. The
alpha-L-oxy-LNA is locked in a S-type and therefore the
oligonucleotides that it will form will be more DNA like (Sorensen
et al., J. Amer. Chem. Soc., 2002, 124(10), 2164-76; Rajwanshi et
al., Angew. Chem. Int. Ed., 2000; 39:1656-1659). Molecular
strategies are being developed to modulate unwanted gene expression
that either directly causes, participates in, or aggravates a
disease state. One such strategy involves inhibiting gene
expression with oligonucleotides complementary in sequence to the
messenger RNA of a target gene. The messenger RNA strand is a copy
of the coding DNA strand and is therefore, as the DNA strand,
called the sense strand. Oligonucleotides that hybridise to the
sense strand are called antisense oligonucleotides. Binding of
these strands to mRNA interferes with the translation process and
consequently with gene expression. Zamecnik and co-workers
originally described the Antisense strategy and the principle has
since then attracted a lot of interest (Zamecnik & Stephenson,
PNAS, 1978, 75(1), 280-4; Bennet & Cowset, Biochim. Biophys.
Acta, 1999, 1489, 19-30; Crooke, 1998, Biotechnol. Genet. Eng Rev.,
15, 121-57; Wengel, J. In Antisense Drug Technology; Principles,
Strategies, and Applications; Edited by Crooke, S. T., Ed.; Marcel
Dekker, Inc.: New York, Basel, 2001; pp 339-357).
[0007] It has been a long sought goal to develop drugs with the
capacity to destroy malignant genes base specifically. The
applications of such drugs in e.g. cancer and infections diseases
are self-evident. Native oligonucleotides cannot be employed as
such mainly due to their instability in cellular media and to too
low affinity for the target genes. The wish to develop nucleic acid
probes with improved properties in this regard has been the main
driver behind the massive synthesis effort in the area of nucleic
acid analogue preparation. The most important guideline in this
work has been to design the DNA analogues in such a way that the
DNA analogue would attain the N-type/"RNA"-like conformation that
is associated with the higher affinity of the oligonucleotides to
nucleic acids.
[0008] One of the important mechanisms involved in Antisense is the
RNase H mechanism. RNase H is an intra cellular enzyme that cleaves
the RNA strand in RNA/DNA duplexes. Therefore, in the search for
efficient Antisense oligonucleotides, it has been an important
hallmark to prepare oligonucleotides that can activate RNase H.
However, the prerequisite for an oligonucleotide in this regard is
therefore that the oligo is DNA-like and as stated above most high
affinity DNA analogues induces RNA-like oligonucleotides.
Therefore, to compensate for the lack of RNase H substrate ability
of most DNA analogues (like e.g. 2'-OMe DNA analogue and oxy-LNA)
the oligonucleotides must have segments/consecutive stretches of
DNA and/or phosphorothioates. Depending on the design of the
segments of such oligonucleotides they are usually called Gap-mers,
if the DNA segment is flanked by the segments of the DNA analogue,
Head-mers, if the segment of the DNA analogue is located in the 5'
region of the oligonucleotide, and Tail-mers, if the segment of the
DNA analogue is located in the 3' region of the
oligonucleotide.
[0009] It should be mentioned that other important mechanisms are
involved in Antisense that are not dependent on RNase H activation.
For such oligonucleotides the DNA analogues, like LNA, can be
placed in any combination design (Childs et al. PNAS, 2002, 99(17),
11091-96; Crinelli et al., Nucl. Acid. Res., 2002, 30(11), 2435-43;
Elayadi et al., Biochemistry, 2002, 1, 9973-9981; Kurreck et al.,
Nucl. Acid. Res., 2002, 30(9), 1911-1918; Alayadi & Corey,
Curr. opinion in Inves. Drugs., 2001, 2(4), 558-61; Braasch &
Corey, Chem. & Biol., 2000, 55, 1-7).
[0010] In contrast to the beta-D-oxy-LNA the alpha-L-oxy-LNA has a
DNA-like locked conformation and it has been demonstrated that
alpha-L-oxy-LNA can activate RNase H (Sorensen et al., J. Amer.
Chem. Soc., 2002, 124(10), 2164-76). However, the cleavage rate of
RNase H is much lower compared to DNA in the disclosed designs and
thus, the oligonucleotides in the disclosed designs have not been
shown to be efficient Antisense reagents.
SUMMARY OF THE INVENTION
[0011] The present inventors have found a novel class of
pharmaceuticals which can be used in antisense therapy. Also, the
inventors disclose novel oligonucleotides with improved antisense
properties. The novel oligonucleotides are composed of at least one
Locked Nucleic Acid (LNA) selected from beta-D-thio/amino-LNA or
alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may
also include DNA and/or RNA nucleotides.
[0012] The present inventors have demonstrated that
.alpha.-L-oxy-LNA surprisingly provides the possibility for the
design of improved Antisense oligonucleotides that are efficient
substrates for RNase H. These novel designs are not previously
described and the guidelines developed broaden the design
possibilities of potent Antisense oligonucleotides. Also comprised
in this invention is the disclosure of Antisense oligonucleotides
having other improved properties than the capability of being RNase
H substrates. The oligonucleotides comprise any combination of
LNA-relatives with DNA/RNA, and their analogues, as well as
oxy-LNA. The design of more potent Antisense reagents is a
combination of several features. Among the features of these novel
oligonucleotide designs are increased enzymatic stability,
increased cellular uptake, and efficient ability to recrute RNase
H. Also important is the relation between the length and the
potency of the oligonucleotides (e.g. a 15-mer having the same
potency as a 21-mer is regarded to be much more optimal). The
potency of the novel oligonucleotides comprised in this invention
is tested in cellular in vitro assays and in vivo assays. It is
furthermore showed that the novel designs also improves the in vivo
properties such as better pharmacokinetic/pharmacological
properties and toxicity profiles.
[0013] Beta-D-Oxy-LNA and the Analogues Thio- and Amino LNA:
##STR00001##
DESCRIPTION OF THE DRAWINGS
[0014] FIG. 1: Stability of oligonucleotides containing
beta-D-amino-LNA against SVPD. (Capital letters are LNA, T.sup.N
stands for beta-D-amino-LNA and small letters are DNA. The
oligonucleotide is synthesized on deoxynucleoside-support.
[0015] FIG. 2A: Subcellular distribution in MiaPacaII cells of
FAM-labeled oligonucleotide 2740 transfected with
Lipofectamine2000
[0016] FIG. 2B: Subcellular distribution in MiaPacaII cells of
FAM-labeled oligonucleotide 2774 transfected with
Lipofectamine2000.
[0017] FIG. 2C: Subcellular distribution in MiaPacaII cells of
FAM-labeled oligonucleotide 2752 transfected with
Lipofectamine2000.
[0018] FIG. 2D: Subcellular distribution in MiaPacaII cells of
FAM-labeled oligonucleotide 2746 transfected with
Lipofectamine2000.
[0019] FIG. 3A: Uptake of titriated oligonucleotides (thio=2748;
amino=2754; oxy=2742) in MiaPacaII cells at different
oligonucleotide concentration with Lipofectamine2000 as
transfection agent.
[0020] FIG. 3B: Uptake of titriated oligonucleotides (thio=2748;
amino=2754; oxy=2742) in 15PC3 cells at different oligonucleotide
concentration with Lipofectamine2000 as transfection agent.
[0021] FIG. 4: Down-regulation of Luciferase expression of
oligonucleotides gapmers containing beta-D-amino-LNA or
beta-D-thio-LNA and the corresponding beta-D-oxy-LNA gapmer control
at 50 nM oligonucleotide concentration.
[0022] FIG. 5A: Northern blot of oligonucleotides containing
beta-D-amino-LNA (2754 and 2755), beta-D-thio-LNA (2748 and 2749)
or beta-D-oxy-LNA (2742) at 400 and 800 nM in 15PC3 cells
transfected with Lipofectamine2000.
[0023] FIG. 5B: Quantification of Northern blot of oligonucleotides
containing beta-D-amino-LNA (2754 and 2755), beta-D-thio-LNA (2748
and 2749) or beta-D-oxy-LNA (2742) at 400 and 800 nM in 15PC3 cells
transfected with Lipofectamine2000.
[0024] FIG. 5C: Northern blot of titration oligonucleotides
containing beta-D-amino-LNA (2754 and 2755), beta-D-thio-LNA (2748
and 2749) or beta-D-oxy-LNA (2742).
[0025] FIG. 6: Northern blot analysis of oligonucleotides
containing beta-D-amino-LNA (2754), beta-D-thio-LNA (2748),
alpha-L-oxy-LNA (2776) or beta-D-oxy-LNA (2742) at 50-400 nM in
15PC3 cells transfected with Lipofectamine2000; comparison with the
corresponding mismatch control at 400 nM. Mismatch controls
(thio=2750; amino=2756; alpha=2778) were also analyzed at 30-90 nM
and compared with the corresponding match at 30 nM. Table
containing Northern blot analysis of oligonucleotides containing
beta-D-amino-LNA (2754), alpha-L-oxy-LNA (2776) and beta-D-oxy-LNA
(2742) at 5-40 nM in 15PC3 cells transfected with
Lipofectamine2000; comparison with the corresponding mismatch
controls at 20 nM.
[0026] FIG. 7A: Serum clearance of titriated 2754=amino, 2748=thio
and 2742=oxy after 30 min of intravenous bolus injection. 2131 is
an oligonucleotide gapmer containing beta-D-oxy-LNA used as a
reference.
[0027] FIG. 7B: Biodistribution of titriated 2754=amino, 2748=thio
and 2742=oxy after 30 min of intravenous bolus injection. 2131 is
an oligonucleotide gapmer containing beta-D-oxy-LNA used as a
reference.
[0028] FIG. 7C: Specific tissue uptake of titriated 2754=amino,
2748=thio and 2742=oxy after 30 min of intravenous bolus injection.
2131 is an oligonucleotide gapmer containing beta-D-oxy-LNA used as
a reference.
[0029] FIG. 8A: Total uptake of titriated 2754=amino, 2748=thio and
2742=oxy after 14 days of continuous administration at a 2.5
mg/Kg/day dosage using Alzet osmotic minipumps.
[0030] FIG. 8B: Specific uptake of titriated 2754=amino, 2748=thio
and 2742=oxy after 14 days of continuous administration at a 2.5
mg/Kg/day dosage using Alzet osmotic minipumps.
[0031] FIG. 9: Electrophoresis analysis of .sup.32P-labelled target
RNA degradation products mediated by RNaseH and an oligonucleotide
containing beta-D-amino-LNA. Aliquots taken at 0, 10, 20 and 30 min
for each design. In the drawings, the line is DNA, the rectangle
beta-D-amino- or -thio-LNA.
[0032] FIG. 10: Stability of oligonucleotides containing
beta-D-thio-LNA against SVPD. (Capital letters are LNA, T.sup.S
stands for beta-D-thio-LNA and small letters are DNA. The
oligonucleotide is synthesized on deoxynucleoside-support, t.)
[0033] FIG. 11: FACS analysis of oligonucleotides containing
beta-D-thio-LNA and the corresponding controls.
[0034] FIG. 12: Stability of oligonucleotides containing
alpha-L-oxy-LNA against SVPD. (Capital letters are LNA, 7 stands
for alpha-L-oxy-LNA and small letters are DNA. The oligonucleotide
is synthesized on deoxynucleoside-support, t.)
[0035] FIG. 13: Stability of different oligonucleotides (t.sub.16,
t.sub.s12, T.sub.16, T.sup..alpha..sub.15T) against
S1-endonuclease. (Capital letters are LNA, T.sup..alpha. stands for
alpha-L-oxy-LNA and small letters are DNA. The oligonucleotide is
synthesized on oxy-LNA-support, T.)
[0036] FIG. 14: FACS analysis of oligonucleotides containing
alpha-L-oxy-LNA, and the corresponding controls.
[0037] FIG. 15: Gapmers including alpha-L-oxy-LNA (shadowed in
gray).
[0038] FIG. 16: Down-regulation of Luciferase expression of
oligonucleotides containing alpha-L-oxy-LNA at 50 nM
oligonucleotide concentration.
[0039] FIG. 17A: Mixmers (4-3-1-3-5) containing alpha-L-oxy-LNA.
The numbers stand for the alternate contiguous stretch of DNA or
LNA. In the drawing, the line is DNA, the rectangle beta-D-oxy-LNA,
the gray shadow corresponds to alpha-L-oxy-LNA residues.
[0040] FIG. 17B: Mixmers (4-1-1-5-1-1-3) containing
alpha-L-oxy-LNA. The numbers stand for the alternate contiguous
stretch of DNA or LNA. In the drawing, the line is DNA, the
rectangle beta-D-oxy-LNA, the gray shadow corresponds to
alpha-L-oxy-LNA residues.
[0041] FIG. 18A: Mixmers (4-1-5-1-5) containing alpha-L-oxy-LNA.
The numbers stand for the alternate contiguous stretch of DNA or
alpha-L-oxy-LNA. In the drawing, the line is DNA, the gray shadow
corresponds to alpha-L-oxy-LNA residues.
[0042] FIG. 18B: Mixmers (3-3-3-3-1) containing alpha-L-oxy-LNA.
The numbers stand for the alternate contiguous stretch of DNA or
alpha-L-oxy-LNA. In the drawing, the line is DNA, the gray shadow
corresponds to alpha-L-oxy-LNA residues.
[0043] FIG. 19A: Electrophoresis analysis of .sup.32P-labelled
target RNA degradation products mediated by RNaseH and an
oligonucleotide containing alpha-L-oxy-LNA. Aliquots taken at 0,
10, 20 and 30 min for each design. In the drawings, the line is
DNA, the rectangle beta-D-oxy-LNA, the gray shadow corresponds to
alpha-L-oxy-LNA residues.
[0044] FIG. 19B: Electrophoresis analysis of .sup.32P-labelled
target RNA degradation products mediated by RNaseH and an
oligonucleotide containing alpha-L-oxy-LNA. Aliquots taken at 0,
10, 20 and 30 min for each design. In the drawings, the line is
DNA, the rectangle beta-D-oxy-LNA, the gray shadow corresponds to
alpha-L-oxy-LNA residues.
[0045] FIG. 20A: Tumor growth in nude mice treated with the
indicated doses for 14 days using Alzet osmotic minipumps for
MiaPacaII cells.
[0046] FIG. 20B: Tumor growth in nude mice treated with the
indicated doses for 14 days using Alzet osmotic minipumps for
MiaPacaII cells.
[0047] FIG. 20C: Tumor growth in nude mice treated with the
indicated doses for 14 days using Alzet osmotic minipumps for 15PC3
cells.
[0048] FIG. 20D: Tumor growth in nude mice treated with the
indicated doses for 14 days using Alzet osmotic minipumps for 15PC3
cells.
[0049] FIG. 21A: ASAT levels in mice serum after 14-day treatment
using Alzet osmotic minipumps with the indicated oligonucleotides
and at the indicated concentrations. 2722 and 2713 are
oligonucleotides not relevant to this study.
[0050] FIG. 21B: ALAT levels in mice serum after 14-day treatment
using Alzet osmotic minipumps with the indicated oligonucleotides
and at the indicated concentrations. 2722 and 2713 are
oligonucleotides not relevant to this study.
[0051] FIG. 21C: Alkaline phosphatase levels in mice serum after
14-day treatment using Alzet osmotic minipumps with the indicated
oligonucleotides and at the indicated concentrations. 2722 and 2713
are oligonucleotides not relevant to this study.
[0052] FIG. 21D: Dosages used in studies in FIGS. 21A-21C.
[0053] FIG. 22: Monitoring the body temperature of the mice during
the in vivo experiment. 2722 and 2713 are oligonucleotides not
relevant to this study.
[0054] FIG. 23: Special constructs with beta-D-oxy-LNA. The numbers
stand for the alternate contiguous stretch of DNA and
beta-D-oxy-LNA. In the drawing, the line is DNA, the rectangle is
beta-D-oxy-LNA.
[0055] FIG. 24: Down-regulation of Luciferase expression of special
constructs containing beta-D-oxy-LNA (designs 3-9-3-1) at 2 nM
oligonucleotide concentration.
DETAILED DESCRIPTION
[0056] Thus, the present invention in it broadest scope relates to
a pharmaceutical composition comprising a therapeutically active
antisense oligonucleotide construct which (i) comprises at least
one locked nucleic acid unit selected from the group consisting of
amino-LNA and thio-LNA and derivatives thereof; or (ii) comprises
at least two consecutively located locked nucleotide units of which
at least one is selected from the group consisting of
alpha-L-oxy-LNA and derivatives thereof. The antisense construct
can be in the form of a salt or in the form of prodrug or salts of
such prodrug. The invention thus relates to pharmaceutical
compositions in which an active ingredient is a pharmaceutically
acceptable salt, prodrug (such as an ester) or salts of such
prodrug of the above oligonucleotide construct. Both amino- and
thio-LNA can be either alpha or beta configuration, and in (i), the
oligonucleotide construct encompasses constructs with at least one
(such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) units selected from the
group consisting of: alpha-L-thio-LNA, beta-D-thio-LNA,
beta-D-amino-LNA, alpha-L-amino-LNA and derivatives thereof;
optionally in combination with at least one (such as 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more)
further independently selected locked or non-locked nucleotide
units. Examples on these further units are oxy-LNA (such as alpha-L
or beta-D), thio/amino LNA (such as alpha-L or beta-D), a
nucleotide unit which has a 2'-deoxy-erythro-pentofuranosyl sugar
moiety (such as a DNA nucleotide), a nucleotide unit which has a
ribo-pentofuranosyl sugar moiety (such as a RNA nucleotide); and
derivatives thereof. In (ii), the oligonucleotide construct
encompasses constructs with at least two (such as 2, 3, 4, 5, 6, 7,
8, 9, 10 or more) consecutively located nucleotide units, of which
at least one (such as 1, 2, 3, 4, 5, 6, 7 or more) is alpha-L-oxy
LNA units or derivatives thereof. In addition to the alpha-L-oxy
LNA units or derivatives thereof, the sequence of consecutively
located locked nucleotide units optionally comprises other locked
nucleotide units (such as the units defined herein). Besides the
essential two consecutively located locked nucleotide units, the
construct in (ii) optionally comprises one or more (such as 1, 2,
3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or
more) independently selected locked or non-locked nucleotide units
(such as the units defined herein).
[0057] In an interesting embodiment, the invention relates to a
pharmaceutical composition in which the antisense oligonucleotide
construct comprises two adjacently located nucleotide sequences A
and B, where
[0058] A represents a sequence of nucleotide units comprising (i)
at least one locked nucleotide unit selected from the group
consisting of thio-LNA, amino-LNA (both in either alpha-L or beta-D
configuration) and derivatives thereof, or (ii) at least two
consecutively located locked nucleotide units of which at least one
is selected from the group consisting of alpha-L-oxy-LNA and
derivatives thereof; and
[0059] B represents one nucleotide unit or a sequence of nucleotide
units, with the proviso that at least one nucleotide unit in B has
a 2'-deoxy-erythro-pentofuranosyl sugar moiety or a
ribo-pentofuranosyl sugar moiety. Sequence A can additionally
comprise at least one further locked nucleotide unit (such as 2, 3,
4 or 5 units), preferably selected independently from the group
consisting of amino-LNA, thio-LNA (both in either alpha-L or beta-D
configuration), alpha-L-oxy-LNA and derivatives thereof.
[0060] In an other interesting embodiment, the invention relates to
a pharmaceutical composition comprising an oligonucleotide
construct which contains three adjacently located nucleotide
sequences, A, B and C, in the following order (5' to 3'):
[0061] A-B-C or C-B-A, in which
[0062] A represents a sequence comprising at least two
consecutively located locked nucleotide units, at least one of
which is an alpha-L-oxy-LNA unit, and which sequence optionally
contains one or more (such as 2, 3, 4 or 5) non-locked nucleotide
units (such as deoxyribonucleotide units, ribonucleotide units or
derivatives thereof) and/or optionally contains one or more (such
as 2, 3, 4 or 5) locked nucleotide units, such as a unit selected
from the group consisting of oxy-LNA, thio-LNA, amino-LNA (all in
either alpha-L or beta-D configuration) and derivatives
thereof;
[0063] B represents one nucleotide unit or a sequence of nucleotide
units, with the proviso that at least one nucleotide unit in B has
a 2'-deoxy-erythro-pentofuranosyl sugar moiety or a
ribo-pentofuranosyl moiety; and
[0064] C represents a sequence comprising at least two
consecutively located locked nucleotide units, at least one of
which is an alpha-L-oxy-LNA unit, and which sequence optionally
contains one or more (such as 2, 3, 4 or 5) non-locked nucleotide
units (such as deoxyribonucleotide units, ribonucleotide units or
derivatives thereof) and/or optionally contains one or more (such
as 2, 3, 4 or 5) locked nucleotide units, such as a unit selected
from the group consisting of oxy-LNA, thio-LNA, amino-LNA (all in
either alpha-L or beta-D configuration) and derivatives
thereof.
[0065] The invention also relates to an oligonucleotide construct
which comprises at least one nucleotide sequence comprising one or
more nucleotide units selected from the group consisting of
amino-LNA, thio-LNA (in all configurations) and derivatives
thereof; with the proviso that the following oligonucleotide
constructs are excluded:
[0066] (i) 5'-d(GTGAVATGC), 5'-d(GVGAVAVGC), 5'-d(GTGAXATGC),
5'-d(GXGAXAXGC), 5'-d(GXGVXVXGC), in which sequences V represents a
beta-D-amino-LNA thymine unit, and
[0067] X represents a beta-D-methylamino-LNA thymine unit; and
[0068] (ii) 5'-d(GTGAYATGC), 5'-d(GYGAYAYGC) and 5'-d(GYGYYYYGC) in
which sequences Y represents a beta-D-thio-LNA uracil unit.
[0069] The excluded oligonucleotides are previously disclosed by
Singh et al and Kumar et al. (Kumar et al. Bioorg, & Med. Chem.
Lett., 1998, 8, 2219-2222; Singh et al. J. Org. Chem., 1998, 63,
10035-39). It has collectively for the excluded LNA-relatives been
shown that they can be incorporated into oligonucleotides. However,
no biological properties have not been demonstrated or
suggested.
[0070] A presently preferred group of oligonucleotide constructs of
the invention comprises two adjacently located nucleotide
sequences, A and B, where A represents a sequence of nucleotide
units comprising at least one locked nucleotide unit selected from
the group consisting of amino-LNA, thio-LNA (both in either alpha-L
or beta-D) configuration, and derivatives thereof; and B represents
one nucleotide unit or a sequence of nucleotide units, with the
proviso that at least one nucleotide unit in B has a
2'-deoxy-erythro-pentofuranosyl sugar moiety or a
ribo-pentofuranosyl moiety; especially constructs in which B
represents a sequence of nucleotide units, said sequence contains a
subsequence of at least three nucleotide units having
2'-deoxy-erythro-pentofuranosyl sugar moieties, such as 4, 5, 6, 7,
8, 9 or 10 nucleotide units, said subsequence optionally being
spiked with an other nucleotide, preferably an alpha-L-oxy-LNA unit
selected from the group consisting of alpha-L-amino-LNA,
alpha-L-thio-LNA, alpha-L-oxy-LNA and derivatives thereof.
[0071] Also interesting is a construct according which comprises
three adjacently located nucleotide sequences in the following
order (5' to 3'): A-B-C,
[0072] in which the nucleotide sequences A and B are as defined as
above, and C represents a sequence of nucleotide units, which
comprises at least one locked nucleotide unit selected from the
group consisting of amino-LNA, thio-LNA (both in either alpha-L or
beta-D configuration) and derivatives thereof.
[0073] In the above constructs, it is preferred that A has a length
of 2-10 (preferably 2-8, such as 3, 4, 5, 6, 7) nucleotide units; B
has a length of 1-10 (preferably 5-8, such as 6 or 7) nucleotide
units; and C (if present) has a length of 2-10 (preferably 2-8,
such as 3, 4, 5, 6, or 7) nucleotide units; so that the overall
length of the construct is 6-30 (preferably 10-20, more preferably
12-18, such as 13, 14, 15, 16 or 17) nucleotide units.
[0074] A preferred embodiment of the above construct according to
the invention is a construct in which A represents a sequence of
nucleotide units comprising at least two consecutively located
locked nucleotide units (such as 3, 4, 5, 6, 7, 8, 9 or 10 units),
at least one of said locked nucleotide units being selected from
the group consisting of amino-LNA, thio-LNA and derivatives
thereof; C represents a sequence of nucleotide units comprising at
least two consecutively located locked nucleotide units (such as 3,
4, 5, 6, 7, 8, 9 or 10 units), at least one of said locked
nucleotide units being selected from the group consisting of
amino-LNA, thio-LNA (in all configurations) and derivatives
thereof, and/or B represents a sequence of least 2 nucleotide units
(such as 3, 4, 5, 6, 7, 8, 9 or 10 units), which sequence in
addition to the nucleotide unit(s) having
2'-deoxy-erythro-pentofuranosyl sugar moiety(ies) and/or
ribo-pentofuranosyl moiety(ies), comprises nucleotides units which
are selected independently from the group consisting of: locked
nucleotide units (such as alpha-L-oxy-, -thio-, or
-amino-nucleotide units) and derivatives thereof.
[0075] An other embodiment of the invention relates to an
oligonucleotide construct which contains three adjacently located
nucleotide sequences, A, B and C, in the following order (5' to
3'): A-B-C or C-B-A, in which
[0076] A represents a sequence comprising at least two
consecutively located locked nucleotide units, at least one of
which is an alpha-L-oxy-LNA unit, and which sequence optionally
contains one or more (such as 2, 3, 4 or 5) non-locked nucleotide
units (such as deoxyribonucleotide units, ribonucleotide units or
derivatives thereof) and/or optionally contains one or more (such
as 2, 3, 4 or 5) locked nucleotide units, such as a unit selected
from the group consisting of oxy-LNA, thio-LNA, amino-LNA (all in
either alpha or beta configuration) and derivatives thereof;
[0077] B represents one nucleotide unit or a sequence of nucleotide
units, with the proviso that at least one nucleotide unit in B has
a 2'-deoxy-erythro-pentofuranosyl sugar moiety or a
ribo-pentofuranosyl moiety; and
[0078] C represents a sequence comprising at least two
consecutively located locked nucleotide units, at least one of
which is an alpha-L-oxy-LNA unit, and which sequence optionally
contains one or more (such as 2, 3, 4 or 5) non-locked nucleotide
units (such as deoxyribonucleotide units, ribonucleotide units or
derivatives thereof) and/or optionally contains one or more (such
as 2, 3, 4 or 5) locked nucleotide units, such as a unit selected
from the group consisting of oxy-LNA, thio-LNA, amino-LNA (all in
either alpha or beta configuration) and derivatives thereof. It is
preferred that A has a length of 2-10 (preferably 2, 3, 4, 5, 6, 7,
or 8) nucleotide units; B has a length of 1-10 (preferably 5, 6, 7,
or 8) nucleotide units;
[0079] C has a length of 2-10 (preferably 2, 3, 4, 5, 6, 7, or 8)
nucleotide units; so that the overall length of the construct is
8-30 (preferably 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20)
nucleotide units.
[0080] An other interesting embodiment is a construct in which A
represents a sequence of nucleotide units comprising at least three
consecutively located locked nucleotide units, at least one of said
locked nucleotide units being selected from the group consisting of
alpha-L-oxy-LNA and derivatives thereof; C represents a sequence of
nucleotide units comprising at least three consecutively located
locked nucleotide units, at least one of said locked nucleotide
units being selected from the group consisting of alpha-L-oxy-LNA
and derivatives thereof; and/or B represents a sequence of least 2
nucleotide units (such as 3, 4, 5, 6, 7, 8, 9 or 10 units), which
sequence in addition to the nucleotide unit(s) having
2'-deoxy-erythro-pentofuranosyl sugar moiety(ies) and/or
ribo-pentofuranosyl moiety(ies), comprises nucleotide units which
are selected independently from the group consisting of: locked
nucleotide units (such as alpha-L-oxy-, -thio-, or
-amino-nucleotide units) and derivatives thereof. Especially
preferred is a construct in which A and C comprises at least one
alpha-L-oxy-LNA or alpha-L-thio-LNA unit located adjacent to B.
[0081] In a further embodiment, the invention relates to an
oligonucleotide which has the formula (in 5' to 3' order): A-B-C-D,
in which A represents a sequence of locked nucleotide units; B
represents a sequence of non-locked nucleotide units, preferably at
least one unit has a 2'-deoxy pentofuranose sugar moiety, in which
sequence 1 or 2 nucleotide units optionally are substituted with
locked nucleotide units, preferably alpha-L-oxy-LNA; C represents a
sequence of locked nucleotide units; and D represents a non-locked
nucleotide unit or a sequence of non-locked nucleotide units. It is
preferred that A has a length of 2-6 (preferably 3, 4 or 5)
nucleotide units; B has a length of 4-12 (preferably 6, 7, 8, 9, 10
or 11) nucleotide units; C has a length of 1-5 (preferably 2, 3, or
4) nucleotide units; D has a lenght of 1-3 (preferably 1-2)
nucleotide units; and that the overall length of the construct is
8-26 (preferably 12-21) nucleotide units. In presently preferred
construct, A has a length of 4 nucleotide units; B has a length of
7-9, preferably 8, nucleotide units; C has a length of 3 nucleotide
units; D has a length of 1 nucleotide unit; and the overall length
of the construct is 15-17 (preferably 16) nucleotide units. It is
further preferred that the locked nucleotide units in A and C are
beta-D-oxy-LNA units or derivatives thereof.
[0082] The oligonucleotide constructs according to the invention
can contain naturally occurring phosphordiester internucleoside
linkages, as well as other internucleoside linkages as defined in
this specification. Examples on internucleoside linkages are
linkages selected from the group consisting of
--O--P(O).sub.2--O--, --O--P(O,S)--O--, --O--P(S).sub.2--O--,
--NR.sup.H--P(O).sub.2--O--, --O--P(O,NR.sup.H)--O--,
--O--PO(R'')--O--, --O--PO(CH.sub.3)--O--, and
--O--PO(NHR.sup.N)--O--, where R.sup.H is selected form hydrogen
and C.sub.1-4-alkyl, and R'' is selected from C.sub.1-6-alkyl and
phenyl.
[0083] In a further embodiment, the invention relates to an
oligonucleotide construct which comprises at least one locked
nucleotide unit selected from the group consisting of amino-LNA,
thio-LNA (both in either alpha-L or beta-D configuration),
alpha-L-oxy-LNA, and derivatives thereof; wherein at least one of
the linkages between the nucleotide units is different from the
natural occurring phosphordiester (--O--P(O).sub.2--O--) linker.
Constructs in which the internucleoside linkage (between 3' carbon
and 5' carbon on adjacent (3', 5' dideoxy) nucleosides) selected
from the group consisting of: --O--P(O,S)--O--,
--O--P(S).sub.2--O--, --NR.sup.H--P(O).sub.2--O--,
--O--P(O,NR.sup.H)--O--, --O--PO(R'')--O--, --O--PO(CH.sub.3)--O--,
and --O--PO(NHR.sup.N)--O--, where R.sup.H is selected form
hydrogen and C.sub.1-4-alkyl, and R'' is selected from
C.sub.1-6-alkyl and phenyl, is presently preferred, and the
phoshorothioate internucleoside linkage is presently most
preferred.
[0084] An embodiment of the oligonucleotide constructs according to
the invention relates to such constructs that are able to mediate
enzymatic inactivation (at least partly) of the target nucleic acid
(eg. a RNA molecule) for the construct. Constructs that mediate
RNase H cutting of the target are within the scope of the present
invention. Thus, the present invention relates to constructs that
are able to recruit RNase, especially constructs in which sequence
B represents a sequence of nucleotide units that makes the
construct able to recruit RNase H when hybridised to a target
nucleic acid (such as RNA, mRNA).
[0085] It should be understood that the invention also relates to a
pharmaceutical composition which comprises a least one antisense
oligonucleotide construct of the invention as an active ingredient.
It should be understood that the pharmaceutical composition
according to the invention optionally comprises a pharmaceutical
carrier, and that the pharmaceutical composition optionally
comprises further antisense compounds, chemotherapeutic compounds,
antiinflammatory compounds and/or antiviral compounds.
[0086] The pharmaceutical compositions of the present invention may
be administered in a number of ways depending upon whether local or
systemic treatment is desired and upon the area to be treated.
Administration may be (a) oral (b) pulmonary, e.g., by inhalation
or insufflation of powders or aerosols, including by nebulizer;
intratracheal, intranasal, (c) topical including epidermal,
transdermal, ophthalmic and to mucous membranes including vaginal
and rectal delivery; or (d) parenteral including intravenous,
intraarterial, subcutaneous, intraperitoneal or intramuscular
injection or infusion; or intracranial, e.g., intrathecal or
intraventricular, administration.
[0087] Pharmaceutical compositions and formulations for topical
administration may include transdermal patches, ointments, lotions,
creams, gels, drops, sprays, suppositories, liquids and powders.
Conventional pharmaceutical carriers, aqueous, powder or oily
bases, thickeners and the like may be necessary or desirable.
Coated condoms, gloves and the like may also be useful. Preferred
topical formulations include those in which the oligonucleotides of
the invention are in admixture with a topical delivery agent such
as lipids, liposomes, fatty acids, fatty acid esters, steroids,
chelating agents and surfactants. Compositions and formulations for
oral administration include but is not restricted to powders or
granules, microparticulates, nanoparticulates, suspensions or
solutions in water or non-aqueous media, capsules, gel capsules,
sachets, tablets or minitablets. Compositions and formulations for
parenteral, intrathecal or intraventricular administration may
include sterile aqueous solutions which may also contain buffers,
diluents and other suitable additives such as, but not limited to,
penetration enhancers, carrier compounds and other pharmaceutically
acceptable carriers or excipients.
[0088] Pharmaceutical compositions of the present invention
include, but are not limited to, solutions, emulsions, and
liposome-containing formulations. These compositions may be
generated from a variety of components that include, but are not
limited to, preformed liquids, self-emulsifying solids and
self-emulsifying semisolids.
[0089] The pharmaceutical formulations of the present invention,
which may conveniently be presented in unit dosage form, may be
prepared according to conventional techniques well known in the
pharmaceutical industry. Such techniques include the step of
bringing into association the active ingredients with the
pharmaceutical carrier(s) or excipient(s). In general the
formulations are prepared by uniformly and intimately bringing into
association the active ingredients with liquid carriers or finely
divided solid carriers or both, and then, if necessary, shaping the
product.
[0090] The compositions of the present invention may be formulated
into any of many possible dosage forms such as, but not limited to,
tablets, capsules, gel capsules, liquid syrups, soft gels and
suppositories. The compositions of the present invention may also
be formulated as suspensions in aqueous, non-aqueous or mixed
media. Aqueous suspensions may further contain substances which
increase the viscosity of the suspension including, for example,
sodium carboxymethylcellulose, sorbitol and/or dextran. The
suspension may also contain stabilizers.
[0091] The antisense nucleotide constructs of the invention
encompass, in their broadest scope, any pharmaceutically acceptable
salts, esters, or salts of such esters. Furthermore encompasses the
invention any other compound, which, upon administration to an
animal or a human, is capable of directly or indirectly providing
the biologically active metabolite or residue thereof. The
invention therefore also encompasses prodrugs of the compounds of
the invention and pharmaceutically acceptable salts of such
prodrugs, and other bioequivalents. The term prodrug indicates a
therapeutic agent that is prepared in an inactive form and that is
converted to an active form, a drug, within the body or cells
thereof. The pharmaceutically acceptable salts include but are not
limited to salts formed with cations; acid addition salts formed
with inorganic acids salts formed with organic acids such as, and
salts formed from elemental anions.
[0092] In one embodiment, the present invention employs various
penetration enhancers to effect the efficient delivery of nucleic
acids, particularly oligonucleotides, to the skin of animals or
humans. Most drugs are present in solution in both ionized and
nonionized forms. However, usually only lipid soluble or lipophilic
drugs readily cross cell membranes. It has been discovered that
even non-lipophilic drugs may cross cell membranes if the membrane
to be crossed is treated with a penetration enhancer. In addition
to aiding the diffusion of non-lipophilic drugs across cell
membranes, penetration enhancers also enhance the permeability of
lipophilic drugs.
[0093] Pharmaceutical compositions of the invention include a
pharmaceutical carrier that may contain a variety of components
that provide a variety of functions, including regulation of drug
concentration, regulation of solubility, chemical stabilization,
regulation of viscosity, absorption enhancement, regulation of pH,
and the like. The pharmaceutical carrier may comprise a suitable
liquid vehicle or excipient and an optional auxiliary additive or
additives. The liquid vehicles and excipients are conventional and
commercially available. Illustrative thereof are distilled water,
physiological saline, aqueous solutions of dextrose, and the like.
For water soluble formulations, the pharmaceutical composition
preferably includes a buffer such as a phosphate buffer, or other
organic acid salt. For formulations containing weakly soluble
antisense compounds, micro-emulsions may be employed. Other
components may include antioxidants, such as ascorbic acid,
hydrophilic polymers, such as, monosaccharides, disaccharides, and
other carbohydrates including cellulose or its derivatives,
dextrins, chelating agents, and like components well known to those
in the pharmaceutical sciences. The oligonucleotides may be
encapsulated in liposomes for therapeutic delivery.
[0094] In a certain embodiment, the present invention provides
pharmaceutical compositions containing (a) one or more antisense
compounds and (b) one or more other chemotherapeutic agents which
function by a non-antisense mechanism. When used with the compounds
of the invention, such chemotherapeutic agents may be used
individually (e.g., mithramycin and oligonucleotide), sequentially
(e.g., mithramycin and oligonucleotide for a period of time
followed by another agent and oligonucleotide), or in combination
with one or more other such chemotherapeutic agents or in
combination with radiotherapy.
[0095] Anti-inflammatory drugs, including but not limited to
nonsteroidal anti-inflammatory drugs and corticosteroids, and
antiviral drugs, may also be combined in compositions of the
invention. Two or more combined compounds may be used together or
sequentially.
[0096] In another embodiment, compositions of the invention may
contain one or more antisense compounds, particularly
oligonucleotides, targeted to a first nucleic acid and one or more
additional antisense compounds targeted to a second nucleic acid
target. Two or more combined compounds may be used together or
sequentially.
[0097] Dosing is dependent on severity and responsiveness of the
disease state to be treated, and the course of treatment lasting
from several days to several months, or until a cure is effected or
a diminution of the disease state is achieved. Optimal dosing
schedules can be calculated from measurements of drug accumulation
in the body of the patient.
[0098] Optimum dosages may vary depending on the relative potency
of individual oligonucleotides. Generally it can be estimated based
on EC50s found to be effective in in vitro and in vivo animal
models. In general, dosage is from 0.01 ug to 25 g per kg of body
weight, and may be given once or more daily, weekly, monthly or
yearly, or even once every 2 to 10 years. The repetition rates for
dosing can be estimated based on measured residence times and
concentrations of the drug in bodily fluids or tissues. Following
successful treatment, it may be desirable to have the patient
undergo maintenance therapy to prevent the recurrence of the
disease state.
[0099] The LNA containing antisense compounds of the present
invention can be utilized for diagnostics, therapeutics,
prophylaxis and as research reagents and kits. For therapeutics, an
animal or a human, suspected of having a disease or disorder, which
can be treated by modulating the expression of a gene by
administering antisense compounds in accordance with this
invention. Further provided are methods of treating an animal and
humans, suspected of having or being prone to a disease or
condition, associated with expression of a target gene by
administering a therapeutically or prophylactically effective
amount of one or more of the antisense compounds or compositions of
the invention. Examples of such a diseases are for example
different types of cancer, infectious and inflammatory
diseases.
[0100] In a certain embodiment, the present invention relates to a
method of synthesis of a pharmaceutical compositions, a
oligonucleotides or a construct according to the present
invention.
Definitions
[0101] The term "nucleotide sequence" or "sequence" comprises a
plurality (ie. more than one) nucleosides (or derivatives thereof),
in which sequence each two adjacent nucleosides (or derivatives
thereof) are linked by an internucleoside linker. When the length
of a sequence are defined by a range (such as from 2-10 nucleotide
units), the range are understood to comprise all integers in that
range, i.e. "a sequence of 2-10 nucleotide units" comprises
sequences having 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide
units.
[0102] In the present context, the term "oligonucleotide" (or
oligo, oligomer) means a successive chain of nucleoside units (i.e.
glycosides of heterocyclic bases) connected via internucleoside
linkages.
[0103] By the term "unit" is understood a monomer.
[0104] The term "at least one" comprises the integers larger than
or equal to 1, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,
14, 15, 16, 17 and so forth.
[0105] The term "locked nucleotide" comprises nucleotides in which
the 2' deoxy ribose sugar moiety is modified by introduction of a
structure containing a heteroatom bridging from the 2' to the 4'
carbon atoms. The term includes nucleotides having the following
substructures (the oxygen at the 3' and 5' ends illustrates
examples of the starting point of the internucleoside
linkages):
[0106] beta-D-LNA derivatives:
##STR00002##
[0107] alpha-L-LNA derivatives
##STR00003##
[0108] In both structures, X represents O, S or N--R (R.dbd.H;
C1-C6 alkyl such as methyl, ethyl, propyl, i-propyl, butyl,
i-butyl, t-butyl and pentyl); and n is an integer 1, 2 or 3, so
that the group --(CH2)n- comprises methylen, ethylen or propylen
groups. In these alkylene groups (and the --N(C1-C6 alkyl)- group),
one or more H atoms can be replaced with substituents, such as one
or more substituents selected from the group consisting of halogen
atoms (Cl, F, Br, I), Nitro, C1-6 alkyl or C1-6 alkoxy, both
optionally halogenated.
[0109] In the present context, the term "C.sub.1-6-alkyl" means a
linear, cyclic or branched hydrocarbon group having 1 to 6 carbon
atoms, such as methyl, ethyl, propyl, iso-propyl, butyl,
tert-butyl, iso-butyl, pentyl, cyclopentyl, hexyl, cyclohexyl, in
particular methyl, ethyl, propyl, iso-propyl, tert-butyl, iso-butyl
and cyclohexyl. "C.sub.1-6-alkoxy" means --O--(C1-6-alkyl).
[0110] The term "non-locked nucleotide" comprises nucleotides that
do not contain a bridging structure in the ribose sugar moiety.
Thus, the term comprises DNA and RNA nucleotide monomers
(phosphorylated adenosine, guanosine, uridine, cytidine,
deoxyadenosine, deoxyguanosine, deoxythymidine, deoxycytidine) and
derivatives thereof as well as other nucleotides having a
2'-deoxy-erythro-pentofuranosyl sugar moiety or a
ribo-pentofuranosyl moiety.
[0111] The term "thio-LNA" comprises a locked nucleotide in which X
in the above formulas represents S, and n is 1. Thio-LNA can be in
both beta-D and alpha-L-configuration.
[0112] The term "amino-LNA" comprises a locked nucleotide in which
X in the above formulas represents --NR--, and n is 1. Amino-LNA
can be in both beta-D and alpha-L-configuration.
[0113] The term "oxy-LNA" comprises a locked nucleotide in which X
in the above formulas represents O and n is 1. Oxy-LNA can be in
both beta-D and alpha-L-configuration.
[0114] By the term "alpha-L-LNA" as used herein is normally
understood alpha-L-oxy-LNA (n=1 in the bridging group), and by the
term "LNA" as used herein is understood beta-D-oxy-LNA monomer
wherein n in the bridging group is 1.
[0115] However, derivatives of the above locked LNA's comprise
nucleotides in which n is an other integer than 1.
[0116] By the term "derivatives thereof" in connection with
nucleotides (e.g. LNA and derivatives thereof) is understood that
the nucleotide, in addition to the bridging of the furan ring, can
be further derivatized. For example, the base of the nucleotide, in
addition to adenine, guanine, cytosine, uracil and thymine, can be
a derivative thereof, or the base can be substituted with other
bases. Such bases includes heterocyclic analogues and tautomers
thereof. Illustrative examples of nucleobases are xanthine,
diaminopurine, 8-oxo-N.sup.6-methyladenine, 7-deazaxanthine,
7-deazaguanine, N.sup.4,N.sup.4-ethanocytosin,
N.sup.6,N.sup.6-ethano-2,6-diaminopurine, 5-methylcytosine,
5-(C.sup.3--C.sup.6)-alkynylcytosine, 5-fluorouracil,
5-bromouracil, pseudoisocytosine,
2-hydroxy-5-methyl-4-triazolopyridin, isocytosine, isoguanin,
inosine, N.sup.6-alylpurines, N.sup.6-acylpurines,
N.sup.6-benzylpurine, N.sup.6-halopurine, N.sup.6-vinylpurine,
N.sup.6-acetylenic purine, N.sup.6-acyl purine,
N.sup.6-hydroxyalkyl purine, N.sup.6-thioalkyl purine,
N.sup.2-alkylpurines, N.sup.4-alkylpyrimidines,
N.sup.4-acylpyrimidines, N.sup.4-benzylpurine,
N.sup.4-halopyrimidines, N.sup.4-vinylpyrimidines,
N.sup.4-acetylenic pyrimidines, N.sup.4-acyl pyrimidines,
N.sup.4-hydroxyalkyl pyrimidines, N.sup.6-thioalkyl pyrimidines,
thymine, cytosine, 6-azapyrimidine, including 6-azacytosine, 2-
and/or 4-mercaptopyrimidine, uracil, C.sup.5-alkylpyrimidines,
C.sup.5-benzylpyrimidines, C.sup.5-halopyrimidines,
C.sup.5-vinylpyrimidine, C.sup.5-acetylenic pyrimidine,
C.sup.5-acyl pyrimidine, C.sup.5-hydroxyalkyl purine,
C.sup.5-amidopyrimidine, C.sup.5-cyanopyrimidine,
C.sup.5-nitropyrimidine, C.sup.5-aminopyrimdine,
N.sup.2-alkylpurines, N.sup.2-alkyl-6-thiopurines, 5-azacytidinyl,
5-azauracilyl, trazolopyridinyl, imidazolopyridinyl,
pyrrolopyrimidinyl, and pyrazolopyrimidinyl. Functional oxygen and
nitrogen groups on the base can be protected as necessary or
desired. Suitable protecting groups are well known to those skilled
in the art, and included trimethylsilyl, dimethylhexylsilyl,
t-butyldimenthylsilyl, and t-butyldiphenylsilyl, trityl, alkyl
groups, acyl groups such as acetyl and propionyl, methanesulfonyl,
and p-toluenesulfonyl. Preferred bases include cytosine, methyl
cytosine, uracil, thymine, adenine and guanine. In addition to the
derivatisation of the base, both locked and non-locked nucleotides
can be derivatised on the ribose moiety. For example, a 2'
substituent can be introduced, such as a substituent selected from
the group consisting of halogen (such as fluor), C1-C9 alkoxy (such
as methoxy, ethoxy, n-propoxy or i-propoxy), C1-C9 aminoalkoxy
(such as aminomethoxy and aminoethoxy), allyloxy, imidazolealkoxy,
and polyethyleneglycol, or a 5' substituent (such as a substituent
as defined above for the 2' position) can be introduced.
[0117] By the terms "internucleoside linkage" and "linkage between
the nucleotide units" (which is used interchangeably) are to be
understood the divalent linker group that forms the covalent
linking of two adjacent nucleosides, between the 3' carbon atom on
the first nucleoside and the 5' carbon atom on the second
nucleoside (said nucleosides being 3',5' dideoxy). The
oligonucleotides of the present invention comprises sequences in
which both locked and non-locked nucleotides independently can be
derivatised on the internucleoside linkage which is a linkage
consisting of preferably 2 to 4 groups/atoms selected from
--CH.sub.2--, --O--, --S--, --NR.sup.H--, >C.dbd.O,
>C.dbd.NR.sup.H, >C.dbd.S, --Si(R'').sub.2--, --SO--,
--S(O).sub.2--, --P(O).sub.2--, --PO(BH.sub.3)--, --P(O,S)--,
--P(S).sub.2--, --PO(R'')--, --PO(OCH.sub.3)--, and
--PO(NHR.sup.H)--, where R.sup.H is selected form hydrogen and
C.sub.1-6-alkyl, and R'' is selected from C.sub.1-6-alkyl and
phenyl. Illustrative examples of such internucleoside linkages are
--CH.sub.2--CH.sub.2--CH.sub.2--, --CH.sub.2--CO--CH.sub.2--,
--CH.sub.2--CHOH--CH.sub.2--, --O--CH.sub.2--O--,
--O--CH.sub.2--CH.sub.2--, --O--CH.sub.2--CH(R5)-,
--CH.sub.2--CH.sub.2--O--, --NR.sup.H--CH.sub.2--CH.sub.2--,
--CH.sub.2--CH.sub.2--NR.sup.H--, --CH.sub.2--NR.sup.H--CH.sub.2--,
--O--CH.sub.2--CH.sub.2--NR.sup.H--, --NR.sup.H--CO--O--,
--NR.sup.H--CO--NR.sup.H--, --NR.sup.H--CS--NR.sup.H--,
--NR.sup.H--C(.dbd.NR.sup.H)--NR.sup.H--,
--NR.sup.H--CO--CH.sub.2--NR.sup.H--, --O--CO--O--,
--O--CO--CH.sub.2--O--, --O--CH.sub.2--CO--O--,
--CH.sub.2--CO--NR.sup.H--, --O--CO--NR.sup.H--,
--NR.sup.H--CO--CH.sub.2--, --O--CH.sub.2--CO--NR.sup.H--,
--O--CH.sub.2--CH.sub.2--NR.sup.H--, --CH.dbd.N--O--,
--CH.sub.2--NR.sup.H--O--, --CH.sub.2--O--N(R5)-,
--CH.sub.2--O--NR.sup.H--, --CO--NR.sup.H--CH.sub.2--,
--CH.sub.2--NR.sup.H--O--, --CH.sub.2--NR.sup.H--CO--,
--O--NR.sup.H--CH.sub.2--, --O--NR.sup.H--, --O--CH.sub.2--S--,
--S--CH.sub.2--O--, --CH.sub.2--CH.sub.2--S--,
--O--CH.sub.2--CH.sub.2--S--, --S--CH.sub.2--CH(R5)-,
--S--CH.sub.2--CH.sub.2--, --S--CH.sub.2--CH.sub.2--O--,
--S--CH.sub.2--CH.sub.2--S--, --CH.sub.2--S--CH.sub.2--,
--CH.sub.2--SO--CH.sub.2--, --CH.sub.2--SO.sub.2--CH.sub.2--,
--O--SO--O--, --O--S(O).sub.2--O--, --O--S(O).sub.2--CH.sub.2--,
--O--S(O).sub.2--NR.sup.H--, --NR.sup.H--S(O).sub.2--CH.sub.2--,
--O--S(O).sub.2--CH.sub.2--, --O--P(O).sub.2--O--,
--O--P(O,S)--O--, --O--P(S).sub.2--O--, --S--P(O).sub.2--O--,
--S--P(O,S)--O--, --S--P(S).sub.2--O--, --O--P(O).sub.2--S--,
--O--P(O,S)--S--, --O--P(S).sub.2--S--, --S--P(O).sub.2--S--,
--S--P(O,S)--S--, --S--P(S).sub.2--S--, --O--PO(R'')--O--,
--O--PO(OCH.sub.3)--O--, --O--PO(OCH.sub.2CH.sub.3)--O--,
--O--PO(OCH.sub.2CH.sub.2S--R)--O--, --O--PO(BH.sub.3)--O--,
--O--PO(NHR.sup.N)--O--, --O--P(O).sub.2--NR.sup.H--,
--NR.sup.H--P(O).sub.2--O--, --O--P(O,NR.sup.H)--O--,
--CH.sub.2--P(O).sub.2--O--, --O--P(O).sub.2--CH.sub.2--, and
--O--Si(R'').sub.2--O--; where R5 is selected from hydrogen and
C.sub.1-6-alkyl, R.sup.H is selected form hydrogen and
C.sub.1-6-alkyl, and R'' is selected from C.sub.1-6-alkyl and
phenyl.
[0118] --CH.sub.2--CO--NR.sup.H--, --CH.sub.2--NR.sup.H--O--,
--S--CH.sub.2--O--, --O--P(O).sub.2--O--, --O--P(O,S)--O--,
--O--P(S).sub.2--O--, --NR.sup.H--P(O).sub.2--O--,
--O--P(O,NR.sup.H)--O--, --O--PO(R'')--O--, --O--PO(CH.sub.3)--O--,
and --O--PO(NHR.sup.N)--O--, where R.sup.H is selected from
hydrogen and C.sub.1-6-alkyl, and R'' is selected from
C.sub.1-6-alkyl and phenyl, are especially preferred.
[0119] The nucleotides units may also contain a 3'-Terminal group
or a 5'-terminal group, preferably --OH.
[0120] By the term "able to recruit RNase H" is understood that the
an oligonucleotide construct, in order to elicit RNase H enzyme
cleavage of a target nucleic acid (such as target mRNA), must
include a segment or subsequence that is of DNA type. This means
that at least some nucleotide units of the oligonucleotide
construct (or a subsequence thereof) must have
2'-deoxy-erythro-pentofuranosyl sugar moieties. A subsequence
having more than three consecutive, linked
2'-deoxy-erythro-pentofuranosyl containing nucleotide units likely
is necessary in order to elicit RNase H activity upon hybridisation
of an oligonucleotide construct of the invention with a target
nucleic acid, such as a RNA. Preferably, a sequence which is able
to recruit RNase H contains more than three consecutively located
nucleotides having 2'-deoxy-erythro-pentofuranosyl sugar moieties,
such as 4, 5, 6, 7, 8 or more units. However, such a subsequence of
consecutively located nucleotides having
2'-deoxy-erythro-pentofuranosyl sugar moieties can by spiked (ie.
one or more (such as 1, 2, 3, 4, or more) nucleotides being
replaced) with other nucleotides, preferably alpha-L-oxy, thio- or
amino-LNA units or derivatives thereof.
[0121] The term "pharmaceutically acceptable salt" is well known to
the person skilled in the art.
[0122] Examples of such pharmaceutically acceptable salts are the
iodide, acetate, phenylacetate, trifluoroacetate, acrylate,
ascorbate, benzoate, chlorobenzoate, dinitrobenzoate,
hydroxybenzoate, methoxybenzoate, methylbenzoate,
o-acetoxybenzoate, naphthalene-2-benzoate, bromide, isobutyrate,
phenylbutyrate, g-hydroxybutyrate, b-hydroxybutyrate,
butyne-1,4-dioate, hexyne-1,4-dioate, hexyne-1,6-dioate, caproate,
caprylate, chloride, cinnamate, citrate, decanoate, formate,
fumarate, glycollate, heptanoate, hippurate, lactate, malate,
maleate, hydroxymaleate, malonate, mandelate, mesylate, nicotinate,
isonicotinate, nitrate, oxalate, phthalate, terephthalate,
phosphate, monohydrogenphosphate, dihydrogenphosphate,
metaphosphate, pyrophosphate, propiolate, propionate,
phenylpropionate, salicylate, sebacate, succinate, suberate,
sulfate, bisulfate, pyrosulfate, sulfite, bisulfite, sulfonate,
benzenesulfonate, p-bromophenylsulfonate, chlorobenzenesulfonate,
propanesulfonate, ethanesulfonate, 2-hydroxyethanesulfonate,
methanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate,
p-toluenesulfonate, xylenesulfonate, tartarate, and the like.
EXPERIMENTAL
[0123] Oligonucleotide Synthesis
[0124] Oligonucleotides were synthesized using the phosphoramidite
approach on an Expedite 8900/MOSS synthesizer (Multiple
Olionucleotide Synthesis System) at 1 .mu.M scale. At the end of
the synthesis (DMT-on) the oligonucleotides were cleaved from the
solid support using aqueous ammonia for 1 h at room temperature,
and further deprotected for 4 h at 65.degree. C. The crudes were
purified by reverse phase HPLC. After the removal of the DMT-group,
the oligonucleotides were characterized by AE-HPLC or RP-HPLC, and
the structure further confirmed by ESI.
[0125] 3'-Exonuclease Stability Study
[0126] Snake venom phosphodiesterase (SVPD, Amersham Pharmacia)
assays were performed using 26 .mu.g/mL oligonucleotide, 0.3
.mu.g/mL enzyme at 37.degree. C. in a buffer of 50 mM Tris-HCl, 10
mM MgCl.sub.2, pH 8. The enzyme was shown to maintain its activity
under these conditions for at least 2 h. Aliquots of the enzymatic
digestion were removed at the indicated times, quenched by heat
denaturation for 3 min and stored at -20.degree. C. until analysis
by RP-HPLC.
[0127] S1-Endonuclease Stability Study
[0128] S1 endonuclease (Amersham Pharmacia) assays were performed
using 1.5 .mu.mol oligonucleotide and 16 U/mL enzyme at 37.degree.
C. in a buffer of 30 mM NaOAc, 100 mM NaCl, 1 mM ZnSO.sub.4, pH
4.6. The enzyme was shown to maintain its activity under these
conditions for at least 2 h. Aliquots of the enzymatic digestion
were removed at the indicated times, quenched by freezing-drying,
and stored at -20.degree. C. until analysis by either RP-HPLC and
ES-MS or polyacrylamide electrophoresis.
[0129] Luciferase Assay
[0130] The X1/5 Hela cell line (ECACC Ref. No: 95051229), which is
stably transfected with a "tet-off" luciferase system, was used. In
the absence of tetracycline the luciferase gene is expressed
constitutively. The expression can be measured as light in a
luminometer, when the luciferase substrate, luciferin has been
added.
[0131] The X1/5 Hela cell line was grown in Minimum Essential
Medium Eagle (Sigma M2279) supplemented with 1.times. Non Essential
Amino Acid (Sigma M7145), 1.times. Glutamax I (Invitrogen
35050-038), 10% FBS calf serum, 25 .mu.g/ml Gentamicin (Sigma
G1397), 500 .mu.g/ml G418 (Invitrogen 10131-027) and 300 .mu.g/ml
Hygromycin B (invitrogen 10687-010). The X1/5 Hela cells were
seeded at a density of 8000 cells per well in a white 96 well plate
(Nunc 136101) the day before the transfection. Before the
transfection, the cells were washed one time with OptiMEM
(Invitrogen) followed by addition of 40 .mu.l of OptiMEM with 2
.mu.g/ml of Lipofectamine2000 (Invitrogen). The cells were
incubated for 7 minutes before addition of the oligonucleotides. 10
.mu.l of oligonucleotide solutions were added and the cells were
incubated for 4 hours at 37.degree. C. and 5% CO.sub.2. After the 4
hours of incubation the cells were washed once in OptiMEM and
growth medium was added (100 .mu.l). The luciferase expression was
measure the next day.
[0132] Luciferase expression was measured with the Steady-Glo
luciferase assay system from Promega. 100 .mu.l of the Steady-Glo
reagent was added to each well and the plate was shaken for 30 s at
700 rpm. The plate was read in Luminoskan Ascent instrument from
ThermoLabsystems after 8 min of incubation to complete total lysis
of the cells. The luciferase expression is measured as Relative
Light Units per seconds (RLU/s). The data was processed in the
Ascent software (v2.6) and graphs were drawn in SigmaPlot2001.
[0133] RNaseH Assay
[0134] 25 nM RNA was incubated in the presence of a 10-fold excess
of various complementary oligonucleotides in 1.times.TMK-glutamate
buffer (20 mM Tris acetate, 10 mM magnesium acetate and 200 mM
potassium glutamate, pH 7.25) supplied with 1 mM DTT in a reaction
volume of 40 .mu.l. The reactions were preincubated for 3 minutes
at 65.degree. C. followed by 15 minutes at 37.degree. C. before
addition of RNase H (Promega, Cat. #4285). 0.2 U of RNase H was
added, and samples were withdrawn (6 .mu.l) to formamide dye (3
.mu.l) on ice at the time points 0, 10, 20 and 30 minutes after
RNase H addition. 3 .mu.l of the 0, 10, 20 and 30 minutes samples
were loaded on a 15% polyacrylamide gel containing 6M urea and
0.9.times. Tris borate/EDTA buffer. The gel was 0.4 mm thick and
ran at 35 watt as the limiting parameter for 2 hours. The gel was
dried for 60 minutes at 80.degree. C., followed by ON exposure on
Kodak phosphorscreen. The Kodak phosphorscreen was read in a
Bio-Rad FX instrument and the result was analysed in Bio-Rad
software Quantity One.
[0135] Cellular Assay: Luciferase Target
[0136] Cell Culture: Cell lines 15PC3 (human prostate cancer) and
X1/5 (HeLa cells stably transfected with a Tet-Off luciferase
construct) were used, 15PC3 were kindly donated by F. Baas,
Neurozintuigen lab, Amsterdam, The Netherlands, X1/5 were purchased
from ECACC. 15PC3 were maintained in DMEM+10%
FCS+glutamax+gentamicin and X1/5 were maintained in DMEM+10%
FCS+glutamax+gentamicin+hygromycin+G418 and both cell lines were
passaged twice weekly.
[0137] Transfection: Cells were seeded at 150000 cells pr. well in
12-well plates the day before transfection. For transfection with
lipid, Lipofectamine 2000 (GIBCO BRL) was mixed with OptiMem and
300 .mu.l of the mixture was added to each well and incubated for 7
min. before addition of 100 .mu.l oligo diluted in OptiMem. For
each cell line, the optimal Lipofectamine 2000 was determined, for
X1/5, the optimal Lipofectamine concentration was 2 .mu.g/ml and
for 15PC3 the optimal concentration was 10 .mu.g/ml.
[0138] For transfection without lipid, the cells were washed in
OptiMem (GIBCO BRL) and 300 .mu.l OptiMem was added to each well.
Working stocks of 200 .mu.M were prepared of each oligonucleotide
to be tested and added to each well obtaining the desired
concentration. For mock controls, oligonucleotide was substituted
with water in both protocols. The cells were incubated with the
oligonucleotide for 4 h at 37.degree. C. and 5% CO.sub.2 in a
humidified atmosphere and subsequently washed in OptiMem before
complete growth medium was added. The cells were incubated for an
additional 20 h.
[0139] For FACS analysis, cells were harvested by trypsination and
washed twice in Cell Wash (BD) and resuspended in 1.times. Cell Fix
(BD).
[0140] FACS analysis: FACS analysis was performed on a FACSCalibur
(BD), settings were adjusted on mock controls. Data analysis was
performed using the Cell Quest Pro software (BD).
[0141] Assisted Cellular Uptake
[0142] Transfections were performed in 6 well culture plates on
microscope glass coverslips with FAM-labeled oligonucleotides at
400 nM. Transfections were done with either DAC30 (Eurogentec) or
Lipofectamine 2000 as liposomal transfection agents for 5 h in
serum free DMEM at 37.degree. C. Immediately after the transfection
period, the cells were washed with PBS and fixed with 4%
paraformaldehyde.
[0143] Cell Lines: Ha-Ras Target
[0144] Prostate cancer cell line 15PC3 and pancreatic carcinoma
cell line MiaPacaII were maintained by serial passage in Dulbecco's
modified Eagle's medium (DMEM). Cells were grown at 37.degree. C.
and 5% CO.sub.2. Media were supplemented with 10% fetal calf serum,
2 mM glutamine, 100 U/mL penicillin and 100 .mu.g/mL
streptomycin.
[0145] Transfections: Ha-Ras Target
[0146] Cell transfections were performed with 15PC3 cells plated in
6 well culture plates. The cells were plated (70% confluent) the
day before transfection. The transfections were usually performed
using lipofectamine 2000 (Invitrogen) according to the
manufacturer's instructions, except for using serum free DMEM.
Cells were transfected for 5 hours. Afterwards the medium was
replaced with fresh DMEM. We also compared Lipofectamine 2000 with
DAC30 (Eurogentec). When DAC30 was used the protocol described in
Ten Asbroek et al. (NAR 28, 1133-1138) was followed.
[0147] For Fluorescence studies the cells were plated on glass
cover slips in 6 well culture plates. Transfections were performed
as described above but using FAM labeled oligonucleotides. At the
time of analysis, the cells were fixed on the glass in 4%
paraformaldehyde and sealed on microscope glass in Vectashield
mounting medium (Vector Laboratories Inc.). Fluorescence microscopy
was done with a Vanox Microscope and appropriate filters.
[0148] mRNA Analysis: Ha-Ras Target
[0149] After 20 hours the cells were harvested in TRIZOL
(Invitrogen), 1 ml per well. The RNA was isolated according to the
manufacturer's instructions for TRIZOL. The RNA was separated on
glyoxal gels containing 1% agarose following standard protocols.
RNA was subsequently blotted onto Hybond N+ membrane (Amersham) in
20.times.SSC. After the transfer, the RNA was UV cross-linked, and
then the membrane was baked for 2 hours at 80.degree. C.
Hybridizations and post-hybridization washes were done according to
Church and Gilbert (PNAS 81, 1991-1995). The Ha-Ras probe used was
generated using Ha-Ras primers according to Sharpe et al. (J. A M.
Soc. Nephrol. 11 1600-1606) cloned into pGEM-T Easy vector
(Promega). The loadings of the Ha-Ras mRNA levels were corrected by
using a 28S probe as described in Ten Asbroek et al. (NAR 28,
1133-1138).
[0150] Biodistribution Studies
[0151] The animal experiments were approved by the ethical
committee and are registered under No. DNL19.
[0152] Tritium labeling of oligonucleotides was performed using the
heat exchange method described by Graham et al. (Graham, M. J.,
Freier, S. M., Crooke, R. M., Ecker, D. J., Maslova, R. N., and
Lesnik, E. A. (1993). Tritium labeling of antisense
oligonucleotides was carried out by exchange with tritiated water.
Nucleic Acids Res., 21: 3737-3743). The only two introduced
differences to the protocol were that only 1 mg was labeled per
oligonucleotide and that the separation of free tritium from the
labeled oligonucleotide was done by 3.times.G10 30 cm Sephadex
columns (the columns were made using 10 ml plastic pipettes).
Radioactivity in all samples was counted after dissolving the
samples in Ultima Gold (Packard) scintillation fluid, and using a
scintillation counter.
[0153] For the biodstribution studies, female nude mice (NMRI
nu/nu, Charles River Netherlands, Maastricht, The Netherlands) with
15PC3 and MiapacaII xenografts were used. See the in vivo
experiment section for further details.
[0154] Tissue distribution studies of tritiated oligonucleotides
were performed according to Bijsterbosch et al. (Bijsterbosch, M.
K., Manoharan, M., Rump, E. T., De Vrueh, R. L., van Veghel, R.,
Tivel, K. L., Biessen, E. A., Bennett, C. F., Cook, P. D., and van
Berkel T. J. (1997) In vivo fate of phosphorothioate antisense
oligodeoxynucleotides: predominant uptake by scavenger receptors on
endothelial liver cells. Nucleic Acids Res., 25: 3290-3296). The
radioactivity in the different organs was corrected for serum
present at the time of sampling as determined by the distribution
of .sup.125I-BSA (personal communication K. Kruijt, University of
Leiden, the Netherlands).
[0155] The oligonucleotides were either administrated by bolus
injection in the lower vena cava (circulation for 30 minutes) or
using Alzet osmotic minipumps (see in vivo experiment section), for
a prolonged systemic circulation. Tissue samples were dissolved in
5 M NaOH at 65.degree. C. and subsequently mixed with 10 volumes of
Ultima Gold scintillation fluid. Serum and urine can be counted by
mixing directly with Ultima gold.
[0156] In Vivo Experiment
[0157] The animal experiments were approved by the ethical
committee and are registered under No. DNL19. The detailed
protocols of the animal studies are described in two publications:
Tumor genotype-specific growth inhibition in vivo by antisense
oligonucleotides against a polymorphic site of the large subunit of
human RNA polymerase II. Fluiter K, ten Asbroek A L, van Groenigen
M, Nooij M, Aalders M C, Baas F. Cancer Res 2002 Apr. 1;
62(7):2024-2028
[0158] In vivo tumor growth inhibition and biodistribution studies
of locked nucleic acid (LNA) antisense oligonucleotides. Fluiter K,
ten Asbroek A L, de Wissel M B, Jakobs M E, Wissenbach M, Olsson H,
Olsen O, Oerum H, Baas F. Nucleic Acids Res 2003 Feb. 1;
31(3):953-962
[0159] Mice: Female NMRI nu/nu (Charles River Netherlands,
Maastricht, The Netherlands). Xenografts: MiaPaca II injected in
the right flank s.c. with Matrigel (collaborative biomedical
products Bedford, Mass.); 15PC3 injected in the left flank s.c.
with Matrigel. Osmotic pumps: Alzet 1002 (DURECT Corporation,
Cupertino, Calif.) lot no. 10045-02 Dosage for 2776, 2778
(alpha-L-oxy-LNA), 2742 and 2744 (beta-D-oxy-LNA): 1 and 2.5
mg/kg/day. Control: physiological saline.
[0160] Temperature and animal ID was monitored using: ELAM chips
(IPTT 200) using a DAS 5002 chip reader (BMDS, Seaford, Del.).
[0161] Serum samples were taken for ASAT/ALAT and Alkaline
Phosphatase determination. Aspartate aminotransferase (ASAT) and
alanine aminotransferase (ALAT) levels and alkaline phosphatase in
serum were determined using standard diagnostic procedures with the
H747 (Hitachi/Roche) with the appropriate kits (Roche Diagnostics).
The ALAT/ASAT and Alkaline phosphatase Levels were determined
approx 20 hours post extraction of serum from the animal.
[0162] Results
[0163] Beta-D-Amino-LNA
[0164] Nuclease Stability
[0165] One of the major difficulties encountered using the
naturally occurring phosphodiester oligonucleotides as antisense
probes is their rapid degradation by various nucleolytic activities
in cells, serum, tissues or culture medium. Since the phosphorus
center is the site of nucleolytic attack, many modifications have
been introduced in the internucleoside linkage to prevent enzymatic
degradation. To date, the most commonly employed synthetic
modification is the backbone phosphorothioate analogue, made by
replacing one of the non-bridging oxygen atoms of the
internucleoside linkage by sulfur.
[0166] We wanted to evaluate the effect of introducing the novel
LNA within an oligonucleotide in the presence of nucleases, and to
compare it with the well-studied phosphorothioate oligonucleotides.
The study was carried out with oligothymidylates by blocking the
3'-end with the novel LNA relatives. The oligonucleotide is
synthesized on deoxynucleoside-support (t).
[0167] From FIG. 1, we can appreciate the stability properties,
which confer beta-D-amino-LNA. Oligonucleotides containing
T-monomer of 2'-beta-D-amino-LNA (T.sup.N) present a remarkable
stability against a 3'-exonuclease. Blocking the 3'-end with just
two T.sup.N stops the enzyme from degrading the oligonucleotide at
least for 2 h. See FIG. 1.
[0168] Assisted Cellular Uptake and Subcellular Distribution
[0169] The uptake efficiency of FAM-labeled oligonucleotide
containing beta-D-amino-LNA was measured as the mean fluorescence
intensity of the transfected cells by FACS analysis. Two different
transfection agents were tested (Lipofectamine 2000 and DAC30) in
two different cell lines (MiaPacaII and 15PC3).
TABLE-US-00001 TABLE 1 Oligonucleotides (SEQ ID NOS 1-3,
respectively, in order of appearance) containing beta-D-amino-LNA
used in cellular uptake and subcellular distribution experiments.
Residue c is metilyl-c both for DNA and LNA. DAC30 Lipofectamine
2000 Ref oligonucleotides % cells % uptake % cells % uptake 2753
T.sup.NC.sup.NC.sup.Ng.sub.st.sub.sc.sub.sa.sub.st.sub.sc.sub.sg.sub.-
sc.sub.st.sub.sC.sup.NC.sup.NT.sup.Nc-FAM -- -- 100 100 2752
T.sup.N.sub.sC.sup.N.sub.sC.sup.N.sub.sg.sub.st.sub.sc.sub.sa.sub.st.-
sub.sc.sub.sg.sub.sc.sub.st.sub.sC.sup.N.sub.sC.sup.N.sub.sT.sup.N.sub.sc--
FAM 30 30 100 100 2740
T.sub.sC.sub.sC.sub.sg.sub.st.sub.sc.sub.sa.sub.st.sub.sc.sub.sg.sub.-
sc.sub.st.sub.sC.sub.sC.sub.sT.sub.sc-FAM 80 30 100 100
[0170] Oligonucleotides both fully thiolated (PS, 2752) and
partially thiolated (PO in the flanks and PS in the gap, 2753)
containing beta-D-amino-LNA listed in table 1 were transfected with
good efficiency, see table 1. Both transfection agents, DAC30 and
Lipofectamine, presented good transfection efficiency; however,
Lipofectamine was superior.
[0171] Lipofectamine showed 100% efficiency in all cases: for both
oligonucleotides (2753 and 2752) and in both cell lines. Moreover,
no significant differences in assisted transfection efficiency were
observed between 2752 and 2753.
[0172] The FAM-labeled oligonucleotide 2752 was also used to assay
the subcellular distribution of oligonucleotides containing
beta-D-amino-LNA, see FIG. 2. Most of the staining was detected as
nuclear fluorescence that appeared as bright spherical structures
(the nucleoli is also stained) in a diffuse nucleoplasmic
background, as well as some cytoplasmic staining in bright punctate
structures. The observed distribution patterns were similar for
15PC3 and MiaPacaII.
[0173] The subcellular distribution of beta-D-amino-LNA was
comparable to the one observed with beta-D-oxy-LNA, 2740.
[0174] The uptake efficiency was also measured with tritium-labeled
oligonucleotide 2754 (see table 3 and FIG. 3) at different
concentrations 100, 200, 300 and 400 nM, using Lipofectamine2000 as
transfection agent, both in MiaPacaII and 15PC3 cells, and compared
with the equivalent beta-D-oxy-LNA, 2742 (see table 3). 2754 shows
lower uptake than 2742.
[0175] Antisense Activity Assay: Luciferase Target
[0176] It has been shown that beta-D-oxy-LNA does not elicit RNaseH
activity, which is the most common mode of action for an antisense
oligonucleotide targeting the down-stream region of the mRNA.
However, this disadvantage can be overcome by creating chimeric
oligonucleotides composed of beta-D-oxy-LNA and a DNA gap
positioned in the middle of the sequence. A gapmer is based on a
central stretch of 4-12 DNA (gap) typically flanked by 1 to 6
residues of 2'-O modified nucleotides (beta-D-oxy-LNA in our case,
flanks). It was of our interest to evaluate the antisense activity
of oligonucleotides, which contain beta-D-amino-LNA in a gapmer
design, and compare them with beta-D-oxy-LNA/DNA gapmers.
[0177] The oligonucleotides from table 2 were prepared. We decided
to carry out the study with gapmers of 16 nt in length and a gap of
7 nt, which contain 4 residues of beta-D-amino-LNA in one flank and
4 residues of beta-D-oxy-LNA in the other flank, and a thiolated
gap. The FAM group was shown not to affect the antisense ability of
the oligonucleotides. Therefore, we prepared a FAM-labelled
oligonucleotide to be both tested in the Luciferase assay, and in
the Cellular uptake (unassisted).
[0178] The oligonucleotide, which targets a motif of the mRNA of
the Firefly Luciferase, contains two mismatches in the flanks. Two
C residues of the 5'-end LNA flank were substituted for two Ts for
synthetic reasons. At that point in time, only the T residues were
available. Therefore and in order to be able to establish a correct
comparison, the corresponding beta-D-oxy-LNA control was also
included in the assay. No FAM labeling was necessary in this
case.
TABLE-US-00002 TABLE 2 Oligonucleotide (SEQ ID NOS. 4-5,
respectively, in order of appearance) containing beta-D-amino-LNA
used in the antisense activity assay and the oxy-LNA control
(Capital letters for LNA and small letters for DNA, TN is
beta-D-amino- LNA). Residue c is methyl-c both for LNA. ref
sequence design size U-14
FAM-T.sup.NT.sup.NT.sup.NT.sup.Ng.sub.st.sub.sc.sub.sa.sub.st.sub.sc.-
sub.sg.sub.sTCTTT Amino-LNA in one flank/PS gap of 7 16 mer 2023-m;
TTTTg.sub.st.sub.sc.sub.sa.sub.st.sub.sc.sub.sg.sub.sTCTTT Control
with oxy-LNA 16 mer 02579
[0179] From FIG. 4, we can see that the oligonucleotide with
beta-D-amino-LNA presents good antisense activity at 50 nM
oligonucleotide concentration. The inclusion of beta-D-amino-LNA in
the flanks of an oligonucleotide results in good down-regulation.
We can conclude that the antisense activity of an oligonucleotide
containing beta-D-amino-LNA is at least as good as the parent all
beta-D-oxy-LNA gapmer.
[0180] Antisense Activity Assay: Ha-Ras Target
[0181] It was of our interest to further evaluate the antisense
activity of oligonucleotides containing beta-D-amino-LNA in a
gapmer design, and compare them with beta-D-oxy-LNA gapmers. [0182]
The oligonucleotides from table 3 were prepared. We decided to
carry out the study with oligonucleotides of 16 nt in length and a
gap of 8 nt, which contain 3 residues of beta-D-amino-LNA in each
flank and a different extent of thiolation. 2754 is fully thiolated
(PS), while 2755 is only thiolated in the gap (PO in the flanks and
PS in the gap). The oligonucleotides were designed to target a
motif of the mRNA of Ha-Ras. Different mismatch controls were also
included, 2756 is fully thiolated and 2757 presents thiolation only
in the gap, see table 3. Moreover, the corresponding beta-D-oxy-LNA
gapmers (see table 3, 2742 is all PS, 2744 is the corresponding
mismatch control; 2743 has PS in the gap, 2745 is the corresponding
mismatch control) were also tested.
TABLE-US-00003 [0182] TABLE 3 Oligonucleotides (SEQ ID NOS 6-13,
respectively, in order of appearance) containing beta-D-amino-LNA
and beta-D-oxy-LNA used in the antisense activity experiments.
Residue c is methyl-c both for DNA and LNA. ref oligonucleotides
2755
T.sup.NC.sup.NC.sup.Ng.sub.st.sub.sc.sub.sa.sub.st.sub.sc.sub.sg.sub.-
sc.sub.st.sub.sC.sup.NC.sup.NT.sup.Nc PO/PS 2754
T.sup.N.sub.sC.sup.N.sub.sC.sup.N.sub.sg.sub.st.sub.sc.sub.sa.sub.st.-
sub.sc.sub.sg.sub.sc.sub.st.sub.sC.sup.N.sub.sC.sup.N.sub.sT.sup.N.sub.sc
All PS 2743
TCCg.sub.st.sub.sc.sub.sa.sub.st.sub.sc.sub.sg.sub.sc.sub.st.sub.sCCT-
c PO/PS 2742
T.sub.sC.sub.sC.sub.sg.sub.st.sub.sc.sub.sa.sub.st.sub.sc.sub.sg.sub.-
sc.sub.st.sub.sC.sub.sC.sub.sT.sub.sc All PS 2757
T.sup.NC.sup.NT.sup.Ng.sub.st.sub.sa.sub.sa.sub.st.sub.sa.sub.sg.sub.-
sc.sub.sc.sub.sC.sup.NC.sup.NC.sup.Nc Mismatch control 2756
T.sup.N.sub.sC.sup.N.sub.sT.sup.N.sub.sg.sub.st.sub.sa.sub.sa.sub.st.-
sub.sa.sub.sg.sub.sc.sub.sc.sub.sC.sup.N.sub.sC.sup.N.sub.sC.sup.N.sub.sc
Mismatch control 2745
TCTg.sub.st.sub.sa.sub.sa.sub.st.sub.sa.sub.sg.sub.sc.sub.sc.sub.sCCC-
c Mismatch control 2744
T.sub.sC.sub.sT.sub.sg.sub.st.sub.sa.sub.sa.sub.st.sub.sa.sub.sg.sub.-
sc.sub.sc.sub.sC.sub.sC.sub.sC.sub.sc Mismatch control
[0183] The Ras family of mammalian proto-oncogenes includes three
well-known isoforms termed Ha-Ras (Ha-Ras), Ki-Ras (K-Ras) and
N-Ras. The ras proto-oncogenes encode a group of plasma membrane
associated G-proteins that bind guanine nucleotides with high
affinity and activates several effectors including raf-1, PI3-K
etc. that are known to activate several distinct signaling cascades
involved in the regulation of cellular survival, proliferation and
differentiation.
[0184] Several in vitro (and in vivo) studies have demonstrated
that the Ras family of proto-oncogenes are involved in the
induction of malignant transformation. Consequently, the Ras family
is regarded as important targets in development of anticancer
drugs, and it has been found that the Ras proteins are either
over-expressed or mutated (often leading to constitutive active Ras
proteins) in approximately 25% of all human cancers.
[0185] Interestingly, the ras gene mutations in most cancer types
are frequently limited to only one of the ras genes and are
dependent on tumor type and tissue. Mutations in the Ha-Ras gene
are mainly restricted to urinary tract and bladder cancer.
[0186] The inclusion of beta-D-amino-LNA in the flanks of an
oligonucleotide results in good down-regulation levels. From FIG.
5, we can see that oligonucleotides with beta-D-amino-LNA present
good antisense activity at two different concentrations, 400 and
800 nM. No significant difference in down-regulation can be seen
between oligonucleotides 2755 and 2754, which present a different
degree in thiolation. We can conclude that the antisense activity
of an oligonucleotide containing beta-D-amino-LNA is at least as
good as the parent beta-D-oxy-LNA gapmer. From FIG. 6, a wider
range of concentration was tested. There is a potent
down-regulation between 50-400 nM for 2754. The specificity was
also tested; at 30 nM there is a significant difference in
down-regulation between the mismatch 2756 (less potent) and the
match 2754. Lower concentrations (5-40 nM) were also included from
the table in FIG. 6. Potent down-regulation is observed even at 5
nM for 2754, and these levels of down-regulation are comparable to
the corresponding beta-D-LNA control, 2742. The specificity is also
remarkable, if we compare the antisense activity for 2754 at 20 nM
(8.7% down-regulation) in comparison with the mismatch containing
control 2756 (56.2% down-regulation).
[0187] Biodistribution
[0188] The biodistribution of oligonucleotides containing
beta-D-amino-LNA (tritiated 2754) was also studied, both after i.v.
injection and using Alzet osmotic minipumps. 2754 was administered
to xenografted mice with 15PC3 tumors on the left side and
MiaPacaII tumors on the right side as an intravenous injection, and
the analysis was carried out after 30 min circulation. From FIG. 7,
the serum clearance for 2754 is very rapid, and the biodistribution
looks very similar to the biodistribution pattern presented by the
reference containing beta-D-oxy-LNA; the kidney and the liver (to
lesser extent) are the main sites of uptake, when corrected for
tissue weight.
[0189] Moreover, a group of 4 nude mice xenografted with 15PC3
tumors on the left side and MiaPacaII tumors on the right side were
treated for 72 h with Alzet osmotic minipumps with a 2.5 mg/Kg/day
dosage of tritiated 2754. After the treatment, the radioactivity
present in the different tissues was measured. FIG. 8 shows the
distribution of 2754 in the tissues as a total uptake and as a
specific uptake. It seems that the tissue takes up significantly
better amino-LNA than beta-D-oxy LNA. The main sites of uptake were
liver, muscle, kidney, skin, bone and heart. When corrected for
tissue weight, kidney, heart and liver (lungs and muscle in a lower
extent) were the main uptake sites. This pattern differs to a
certain extent from the one observed for beta-D-oxy-LNA. It is also
noteworthy that the uptake of amino-LNA is significantly better in
tumor tissue than for e.g. beta-D-oxy LNA (see FIGS. 7 and 8).
[0190] RNase H Assay
[0191] Rnase H is a ubiquitous cellular enzyme that specifically
degrades the RNA strand of DNA/RNA hybrids, and thereby inactivates
the mRNA toward further cellular metabolic processes. The
inhibitory potency of some antisense agents seems to correlate with
their ability to elicit ribonuclease H (RNaseH) degradation of the
RNA target, which is considered a potent mode of action of
antisense oligonucleotides. As such, understanding the mechanisms
of catalytic function and substrate recognition for the RNaseH is
critical in the design of potential antisense molecules.
[0192] It was our aim to evaluate the RNaseH activity of gapmers
containing beta-D-amino-LNA. From FIG. 9, we can appreciate a good
cleavage activity for an oligonucleotide containing
beta-D-amino-LNA, as in table 2.
[0193] Beta-D-Thio-LNA
[0194] Nuclease Stability
[0195] As we did for beta-D-amino-LNA, beta-D-thio-LNA was also
evaluated against a 3'-exonuclease (SVPD). The oligonucleotide is
synthesized on deoxynucleoside-support (t). The study was carried
out with oligothymidylates by blocking the 3'-end with
beta-D-thio-LNA.
[0196] From FIG. 10, we can see that the incorporation of just one
T-monomer of 2'-beta-D-thio-LNA (T.sup.S) has a significant effect
in the nucleolytic resistance of the oligonucleotide towards SVPD.
After 2 h digestion more than 80% of the oligonucleotide remains,
while the corresponding beta-D-oxy-LNA oligonucleotide is digested
by the exonuclease, see FIG. 10.
[0197] Unassisted Cellular Uptake
[0198] The efficiency of FAM-labelled oligonucleotide uptake was
measured as the mean fluorescence intensity of the transfected
cells by FACS analysis.
[0199] The transfection without lipid showed distinct differences
between the tested oligonucleotides. The uptake as measured from
mean fluorescence intensity of transfected cells was dose
dependent.
[0200] Gapmers (16 nt in length and gap of 7 nt) containing
beta-D-thio-LNA in the flanks were analysed and compared with the
corresponding beta-D-oxy-LNA gapmers. Beta-D-thio-LNA (one flank
with beta-D-thio-LNA and the other one with oxy-LNA, as in table 5)
showed higher uptake than oligonucleotides containing only oxy-LNA.
The beta-D-thio-LNA oligonucleotides (both all-PO gapmer and gapmer
with PS-gap and PO-flanks) had good uptake efficiency. Specially,
the all-PO gapmer containing beta-D-thio-LNA was far superior to
other all-PO oligonucleotides tested so far, as it can be
appreciated from FIG. 11.
[0201] Assisted Cellular Uptake and Subcellular Distribution
[0202] The uptake efficiency of FAM-labeled oligonucleotide
containing beta-D-thio-LNA was measured as the mean fluorescence
intensity of the transfected cells by FACS analysis. Two different
transfection agents were tested (Lipofectamine 2000 and DAC30) in
two different cell lines (MiaPacaII and 15PC3).
TABLE-US-00004 TABLE 4 Oligonucleotides (SEQ ID NOS 14-15 & 3,
respectively, in order of appearance) containing beta-D-thio-LNA
used in cellular uptake and subcellular distribution experiments.
Residue c is methyl-c both for DNA and LNA. DAC30 Lipofectamine
2000 ref oligonucleotides % cells % uptake % cells % uptake 2747
T.sup.SC.sup.SC.sup.Sg.sub.st.sub.sc.sub.sa.sub.st.sub.sc.sub.sg.sub.-
sc.sub.st.sub.sC.sup.SC.sup.ST.sup.Sc-FAM -- -- 100 100 2746
T.sup.S.sub.sC.sup.S.sub.sC.sup.S.sub.sg.sub.st.sub.sc.sub.sa.sub.st.-
sub.sC.sub.sg.sub.sc.sub.st.sub.sC.sup.S.sub.sC.sup.S.sub.sT.sup.S.sub.sc--
FAM 80 50 100 100 2740
T.sub.sC.sub.sC.sub.sg.sub.st.sub.sc.sub.sa.sub.st.sub.sc.sub.sg.sub.-
sc.sub.st.sub.sC.sub.sC.sub.sT.sub.sc-FAM 80 30 100 100
[0203] Oligonucleotides both fully thiolated (PS, 2746) and
partially thiolated (PO in the flanks and PS in the gap, 2747)
containing beta-D-thio-LNA listed in table 4 were transfected with
good efficiency, see table 4. Both transfection agents, DAC30 and
Lipofectamine, presented good transfection efficiency; however,
Lipofectamine was superior. Lipofectamine showed 100% efficiency in
all cases: for both oligonucleotides (2746 and 2747) and in both
cell lines. Moreover, no significant differences in assisted
transfection efficiency were observed between 2746 and 2747.
[0204] The FAM-labeled oligonucleotide 2746 was also used to assay
the subcellular distribution of oligonucleotides containing
beta-D-thio-LNA, see FIG. 2. Most of the staining was detected as
nuclear fluorescence that appeared as bright spherical structures
(the nucleoli is also stained) in a diffuse nucleoplasmic
background, as well as some cytoplasmic staining in bright punctate
structures. The observed distribution patterns were similar for
15PC3 and MiaPacaII.
[0205] The subcellular distribution of beta-D-thio-LNA was
comparable to the one observed with beta-D-oxy-LNA, 2740.
[0206] The uptake efficiency was also measured with tritium-labeled
oligonucleotide 2748 (see table 6 and FIG. 3) at different
concentrations 100, 200, 300 and 400 nM, using Lipofectamine2000 as
transfection agent, both in MiaPacaII and 15PC3 cells, and compared
with the equivalent beta-D-oxy-LNA, 2742 (see table 6). 2748 shows
superior uptake than 2742.
[0207] Antisense Activity Assay: Luciferase Target
[0208] We also introduced beta-D-thio-LNA in a gapmer design, and
evaluated it in terms of antisense activity.
[0209] The oligonucleotides from table 5 were prepared. We decided
to carry out the study with gapmers of 16 nt in length and a gap of
7 nt, which contain 4 residues of beta-D-thio-LNA in one flank and
4 residues of oxy-LNA in the other flank, and a thiolated gap.
[0210] The FAM group was shown not to affect the antisense ability
of the oligonucleotides. Therefore, we prepared a FAM-labelled
oligonucleotide to be both tested in the Luciferase assay, and in
the Cellular uptake (unassisted).
[0211] The oligonucleotide, which is directed against a motif of
the mRNA of the firefly luciferase, contains two mismatches in the
flanks. Two C residues of the 5'-end LNA flank were substituted for
two T.sup.S for synthetic reasons. At that point in time, only the
T residues were available. Therefore and in order to be able to
establish a correct comparison, the corresponding oxy-LNA control
was also included in the assay. No FAM labeling was necessary in
this case.
TABLE-US-00005 TABLE 5 Oligonucleotide (SEQ ID NOS 16 & 5,
respectively, in order of appearance containing beta-D-thio-LNA
used in the antisense activity assay and the corresponding oxy-LNA
control (Capital letters for LNA and small letters for DNA, TS is
beta-D-thio-LNA). Residue c is methyl-c both for LNA. ref sequence
design size U-16
T.sup.ST.sup.ST.sup.ST.sup.Sg.sub.st.sub.sc.sub.sa.sub.st.sub.sc.sub.-
sg.sub.sTCTTT-FAM Thio-LNA in one flank/PS gap of 7 16 mer 2023-m;
TTTTg.sub.st.sub.sc.sub.sa.sub.st.sub.sc.sub.sg.sub.sTCTTT Control
with oxy-LNA 16 mer 02579
[0212] From FIG. 4, it can be seen that the oligonucleotide with
beta-D-thio-LNA presents good antisense activity at 50 nM
oligonucleotide concentration. Therefore, the inclusion of
beta-D-thio-LNA in the flanks of an oligonucleotide results in good
down-regulation, and is at least as good as the parent all
beta-D-oxy-LNA gapmer.
[0213] Antisense Activity Assay: Ha-Ras Target
[0214] It was of our interest to further evaluate the antisense
activity of oligonucleotides containing beta-D-thio-LNA in a gapmer
design, and compare them with beta-D-oxy-LNA gapmers. [0215] The
oligonucleotides from table 6 were prepared. We decided to carry
out the study with oligonucleotides of 16 nt in length and a gap of
8 nt, which contain 3 residues of beta-D-thio-LNA in each flank and
a different extent of thiolation. 2748 is fully thiolated (PS),
while 2749 is only thiolated in the gap (PO in the flanks and PS in
the gap). The oligonucleotides were designed to target a motif of
the mRNA of Ha-Ras. Different mismatch controls were also included,
2750 is fully thiolated and 2751 presents thiolation only in the
gap, see table 6. Moreover, the corresponding beta-D-oxy-LNA
gapmers (see table 6, 2742 is all PS, 2744 is the corresponding
mismatch control; 2743 has PS in the gap, 2745 is the corresponding
mismatch control) were also tested.
TABLE-US-00006 [0215] TABLE 6 Oligonucleotides (SEQ ID NOS 17-18,
8-9, 19-20 & 12-13, respectively, in order of appearance)
containing beta-D-thio-LNA and beta-D-oxy-LNA used in the antisense
activity experiments. Residue c is methyl-c both for DNA and LNA.
ref oligonucleotides 2749
T.sup.SC.sup.SC.sup.Sg.sub.st.sub.sc.sub.sa.sub.st.sub.sc.sub.sg.sub.-
sc.sub.st.sub.sC.sup.SC.sup.ST.sup.Sc PO/PS 2748
T.sup.S.sub.sC.sup.S.sub.sC.sup.S.sub.sg.sub.st.sub.sc.sub.sa.sub.st.-
sub.sc.sub.sg.sub.sc.sub.st.sub.sC.sup.S.sub.sC.sup.S.sub.sT.sup.S.sub.sc
All PS 2743
TCCg.sub.st.sub.sc.sub.sa.sub.st.sub.sc.sub.sg.sub.sc.sub.st.sub.sCCT-
c PO/PS 2742
T.sub.sC.sub.sC.sub.sg.sub.st.sub.sc.sub.sa.sub.st.sub.sc.sub.sg.sub.-
sc.sub.st.sub.sC.sub.sC.sub.sT.sub.sc All PS 2751
T.sup.SC.sup.ST.sup.Sg.sub.st.sub.sa.sub.sa.sub.st.sub.sa.sub.sg.sub.-
sc.sub.sc.sub.sC.sup.SC.sup.SC.sup.Sc Mismatch control 2750
T.sup.S.sub.sC.sup.S.sub.sT.sup.S.sub.sg.sub.st.sub.sa.sub.sa.sub.st.-
sub.sa.sub.sg.sub.sc.sub.sc.sub.sC.sup.S.sub.sC.sup.S.sub.sC.sup.S.sub.sc
Mismatch control 2745
TCTg.sub.st.sub.sa.sub.sa.sub.st.sub.sa.sub.sg.sub.sc.sub.sc.sub.sCCC-
c Mismatch control 2744
T.sub.sC.sub.sT.sub.sg.sub.st.sub.sa.sub.sa.sub.st.sub.sa.sub.sg.sub.-
sc.sub.sc.sub.sC.sub.sC.sub.sC.sub.sc Mismatch control
[0216] The inclusion of beta-D-thio-LNA in the flanks of an
oligonucleotide results in good down-regulation levels. From FIG.
5, we can see that oligonucleotides with beta-D-thio-LNA present
good antisense activity at two different concentrations, 400 and
800 nM. No significant difference in down-regulation can be seen
between oligonucleotides 2749 and 2748, which present a different
degree in thiolation. However, 2749 presents better levels of
down-regulation, both at 400 and 800 nM. We can conclude that the
antisense activity of an oligonucleotide containing beta-D-thio-LNA
lies in the range of the parent beta-D-oxy-LNA gapmer. From FIG. 6,
a wider range of concentration was tested. There is a potent
down-regulation between 50-400 nM for 2748. The specificity was
also tested; at 30 nM there is a significant difference in
down-regulation between the mismatch 2750 (less potent) and the
match 2748.
[0217] Biodistribution
[0218] The biodistribution of oligonucleotides containing
beta-D-thio-LNA (tritiated 2748) was also studied, both after i.v.
injection and using Alzet osmotic minipumps.
[0219] 2748 was administered to xenografted mice with 15PC3 tumors
on the left side and MiaPacaII tumors on the right side as an
intraveneous injection, and the analysis was carried out after 30
min circulation. From FIG. 7, the serum clearance for 2748 is very
rapid, and the biodistribution looks very similar to the
biodistribution pattern presented by the reference containing
beta-D-oxy-LNA; the kidney and the liver (to lesser extent) are the
main sites of uptake, when corrected for tissue weight.
[0220] Moreover, a group of 4 nude mice xenografted with 15PC3
tumors on the left side and MiaPacaII tumors on the right side were
treated for 72 h with Alzet osmotic minipumps with a 2.5 mg/Kg/day
dosage. After the treatment, the radioactivity present in the
different tissues was measured. FIG. 8 shows the distribution of
2748 in the tissues as a total uptake and as a specific uptake. The
main sites of uptake were liver, muscle, kidney, skin and bone.
When corrected for tissue weight, kidney and liver were the main
uptake sites.
[0221] RNaseH Assay
[0222] We also evaluated gapmer designs that contain
beta-D-thio-LNA, as in table 5, for their ability to recruit RNaseH
activity.
[0223] From FIG. 9, we can see that a beta-D-thio-LNA gapmer
recruits RnaseH activity.
[0224] Alpha-L-oxy LNA
[0225] Nuclease Stability
[0226] The stabilization properties of alpha-L-oxy-LNA were also
evaluated. The study was carried out with oligothymidylates by
blocking the 3'-end with alpha-L-oxy-LNA. The oligonucleotide is
synthesized on deoxynucleoside-support (t). From FIG. 12, we can
see that the introduction of just one alpha-L-T (T.degree.) at the
3'-end of the oligonucleotide represents already a gain of 40%
stability (after 2 h digestion) with respect to the oxy-version,
for which there was actually no gain. The addition of two
modifications contributes even more to the stability of the
oligonucleotide.
[0227] Furthermore, we investigated the effect on stability against
S1-endonuclease of alpha-L-oxy-LNA for a 16mer fully modified
oligothymidylates. The increased stability of these modified
oligonucleotides relative to their deoxynucleotide and
phosphorothioate backbone relatives was compared in order to
carefully assess the contribution of the alpha-L-oxy-LNA
modification.
[0228] After 2 h digestion, most of the alpha-L-oxy-LNA
oligonucleotide remained (over 80% of the full-length product
remained), while neither the oligodeoxynucleotide nor the DNA
phosphorothioate analogue could be detected after 30 min digestion
(see FIG. 13). The same kinetic study against S1-endonuclease was
carried out with a fully modified oxy-LNA oligonucleotide, which
was also very resistant against the S1-endonuclease. Over an 85% of
the full-length product remained after 2 h digestion (see FIG.
13).
[0229] In conclusion, beta-D-oxy-LNA, beta-D-amino-LNA,
beta-D-thio-LNA and alpha-L-oxy-LNA stabilize oligonucleotides
against nucleases. An order of efficiency in stabilization can be
established: DNA phosphorothioates <<oxy-LNA
<.alpha.-L-oxy-LNA <beta-D-amino-LNA <beta-D-thio-LNA.
[0230] Unassisted Cellular Uptake
[0231] The efficiency of FAM-labelled oligonucleotide uptake was
measured as the mean fluorescence intensity of the transfected
cells by FACS analysis. The uptake as measured from mean
fluorescence intensity of transfected cells was dose dependent.
Gapmers (16 nt in length and gap of 7 nt) containing
.alpha.-L-oxy-LNA in the flanks were analysed and compared with the
corresponding beta-D-oxy-LNA gapmer. .alpha.-L-oxy-LNA (in both
flanks) showed higher uptake than the oligonucleotide containing
only beta-D-oxy-LNA. Both all-PO and gapmer with PS-gap had good
uptake efficiency; especially the all-PO gapmer was far superior
than other all PO oligonucleotides tested so far, see FIG. 14 for
FACS analysis.
[0232] Assisted Cellular Uptake and Subcellular Distribution
[0233] The uptake efficiency of FAM-labeled oligonucleotides
containing alpha-L-oxy-LNA was measured as the mean fluorescence
intensity of the transfected cells by FACS analysis. Two different
transfection agents were tested (Lipofectamine 2000 and DAC30) in
two different cancer cell lines (MiaPacaII and 15PC3).
TABLE-US-00007 TABLE 7 Oligonucleotides (SEQ ID NOS 21-22 & 3,
respectively in order of appearance) containing alpha-L-oxy-LNA
used in cellular uptake and subcellular distribution experiments.
Residue c is methyl-c both for DNA and LNA. DAC30 Lipofectamine
2000 ref oligonucleotides % cells % uptake % cells % uptake 2773
T.sup.aC.sup.aC.sup.ag.sub.st.sub.sc.sub.sa.sub.st.sub.sc.sub.sg.sub.-
sc.sub.st.sub.sC.sup.aC.sup.aT.sup.ac-FAM -- -- 100 100 2774
T.sup.a.sub.sC.sup.a.sub.sC.sup.a.sub.sg.sub.st.sub.sc.sub.sa.sub.st.-
sub.sc.sub.sg.sub.sc.sub.st.sub.sC.sup.a.sub.sC.sup.a.sub.sT.sup.a.sub.sc--
FAM 80 30 100 100 2740
T.sub.sC.sub.sC.sub.sg.sub.st.sub.sc.sub.sa.sub.st.sub.sc.sub.sg.sub.-
sc.sub.st.sub.sC.sub.sC.sub.sT.sub.sc-FAM 80 30 100 100
[0234] Oligonucleotides both fully thiolated (PS, 2774) and
partially thiolated (PO in the flanks and PS in the gap, 2773)
containing alpha-L-oxy-LNA listed in table 7 were transfected with
good efficiency, see table 7. Both transfection agents, DAC30 and
Lipofectamine, presented good transfection efficiency; however,
Lipofectamine was superior.
[0235] Lipofectamine showed 100% efficiency in all cases: for both
oligonucleotides (2773 and 2774) and in both cell lines. Moreover,
no significant differences in assisted transfection efficiency were
observed between 2773 and 2774.
[0236] The FAM-labeled oligonucleotide 2774 was also used to assay
the subcellular distribution of oligonucleotides containing
alpha-L-oxy-LNA, see FIG. 2. Most of the staining was detected as
nuclear fluorescence that appeared as bright spherical structures
(the nucleoli is also stained) in a diffuse nucleoplasmic
background, as well as some cytoplasmic staining in bright punctate
structures. The observed distribution patterns were similar for
15PC3 and MiaPacaII.
[0237] The subcellular distribution of alpha-L-oxy-LNA was
comparable to the one observed with beta-D-oxy-LNA, 2740.
[0238] Antisense Activity: Luciferase Target
[0239] Gapmers Containing Alpha-L-Oxy-LNA
[0240] We also wanted to see the antisense activity in a gapmer
oligonucleotides containing alpha-L-oxy-LNA (16 nt in length with a
thiolated 7 nt gap). Two different designs were evaluated.
[0241] First, we substituted two oxy-LNA residues for two
alpha-L-oxy-LNAs in a gapmer against a motif of the mRNA of the
firefly luciferase, and placed the alpha-L-oxy-LNA in the
junctions, see FIG. 15.
[0242] Then, we substituted both flanks with alpha-L-oxy-LNA in the
same construct, see FIG. 15.
[0243] Previously, different oligonucleotides were tested and
compared with the corresponding FAM-labelled molecules, and no
significant difference was appreciated between the free and
FAM-labelled ones. Therefore, we included oligonucleotides from the
Unassisted Cellular Uptake assay in the Luciferase assay study,
assuming that the antisense activity will not be affected by the
presence of the FAM group.
[0244] From FIG. 16, the oligonucleotide with alpha-L-oxy-LNA in
the junctions shows potent antisense activity. It is actually
5-fold better than the corresponding all oxy-LNA gapmer (gap of 7
nt), and slightly better than a gapmer with an optimised 9 nt gap
with oxy-LNA.
[0245] The second design (all alpha-L-oxy-LNAs in both flanks)
presents at least as good down-regulation levels as the observed
for beta-D-oxy-LNA gapmers. We can also conclude that the presence
of the alpha-L-oxy-LNA in a gapmer construct shows good-antisense
activity level.
[0246] alpha-L-oxy-LNA reveals to be a potent tool enabling the
construction of different gapmers, which show good antisense
activity. The placement of alpha-L-oxy-LNA in the junctions results
in a very potent oligonucleotide.
[0247] Short-Sized Gapmers Containing Alpha-L-Oxy-LNA
[0248] As a general rule, the length of the construct is usually
designed to range from 15-25 nucleotide units, in order to ensure
that optimal identification and binding takes place with a unique
sequence in the mammalian genome and not with similar genetically
redundant elements. Statistical analyses specify 11-15 base paired
human sequences as the theoretical lower limits for sufficient
recognition of a single genomic region. In practice, however, a
longer oligonucleotide is commonly used to compensate for low
melting transitions, especially for thiolated oligonucleotides that
have lower affinity.
[0249] As a significant increase in affinity is achieved by the
introduction of oxy-LNA or novel LNA relatives, the design of
potent and short antisense oligonucleotides (<15 nt) should be
enabled.
[0250] The alpha-L-oxy-LNA can play an important role in enabling
the design of short molecules by maintaining the required
high-affinity, but also an optimal gap size. 12 and 14mers against
a motif of the mRNA of the firefly luciferase were evaluated.
[0251] The results are shown in FIG. 16. The presence of
alpha-L-oxy-LNA in the flanks of a 12 (gap of 7 nt) and 14 mer (gap
of 8 nt) correspond to good levels of down-regulation. From FIG.
16.
[0252] In conclusion, alpha-L-oxy-LNA is a potent tool in enabling
the design of short antisense oligonucleotides with significant
down-regulation levels.
[0253] Mixmers Containing Alpha-L-Oxy-LNA
[0254] We also considered other designs containing alpha-L-oxy-LNA
against a motif of the mRNA of the firefly luciferase, which we
called mixmers. They consist of an alternate composition of DNA,
alpha-L-oxy-LNA and beta-D-oxy-LNA. The following figure
illustrates the chosen designs. We named the mixmers by the
alternate number of units of each alpha-L-oxy-LNA, beta-D-oxy-LNA
or DNA composition. See FIG. 17 and table 8 for the different
designs.
TABLE-US-00008 TABLE 8 Mixmers (SEQ ID NOS 23-26,respectively, in
order of appearance) containing alpha-L-oxy-LNA used in this study
(Capital letters for LNA and small letters for DNA, T'' is
alpha-L-oxy-LNA). Residue c is methyl-c both for LNA. ref sequence
mixmer 2023-q
TTCCg.sub.sT.sup.a.sub.sc.sub.sa.sub.st.sub.sc.sub.sg.sub.sT.sup.a.-
sub.sc.sub.sTTT 4-1-1-5-1-1-3 a 2023-r
T.sup.aT.sup.aC.sup.aC.sup.ag.sub.sT.sup.a.sub.sc.sub.sa.sub.st.sub-
.sc.sub.sg.sub.sT.sup.a.sub.sc.sub.sT.sup.aT.sup.aT 4-1-1-5-1-1-3 b
2023-t
TTCCg.sub.st.sub.sc.sub.sA.sup.a.sub.st.sub.sc.sub.sg.sub.sTCTTT
4-3-1-3-5 a 2023-u
TTCC.sup.ag.sub.st.sub.sc.sub.sA.sup.a.sub.st.sub.sc.sub.sg.sub.sTa-
CTTT 4-3-1-3-5 b
[0255] In design 4-1-1-5-1-1-3 (FIG. 17, table 8), we placed two
alpha-L-oxy-LNA residues interrupting the gap, being the flanks
beta-D-oxy-LNA. Furthermore, we interrupted the gap with two
alpha-L-oxy-LNA residues, and substituted both flanks with
alpha-L-oxy-LNA. The presence of alpha-L-oxy-LNA might introduce a
flexible transition between the North-locked flanks (oxy-LNA) and
the alpha-L-oxy-LNA residue by spiking in deoxynucleotide
residues.
[0256] It is also interesting to study design 4-3-1-3-5 (FIG. 17,
table 8), where an alpha-L-oxy-LNA residue interrupts the DNA
stretch. In addition to the alpha-L-oxy-LNA in the gap, we also
substituted two oxy-LNA residues at the edges of the flanks with
two alpha-L-oxy-LNA residues.
[0257] The presence of just one beta-D-oxy-LNA residue (design
4-3-1-3-5) interrupting the stretch of DNAs in the gap results in a
dramatic loss of down-regulation. Just by using alpha-L-oxy-LNA
instead, the design shows significant down-regulation at 50 nM
oligonucleotide concentration, see FIG. 16. The placement of
alpha-L-oxy-LNA in the junctions and one alpha-L-oxy-LNA in the
middle of the gap also shows down-regulation, see FIG. 16.
[0258] The interruption of the gap with two beta-D-oxy-LNAs (design
4-1-1-5-1-1-3) relates also with a loss in antisense activity.
Again the fully substitution of beta-D-oxy-LNA for alpha-L-oxy-LNA
gives significant antisense activity, see FIG. 916.
[0259] alpha-L-oxy-LNA reveals to be a potent tool enabling the
construction of different mixmers, which are able to present high
levels of antisense activity.
[0260] Other Designs
[0261] Other mixmers containing alpha-L-oxy-LNA were studied, see
FIG. 18. Furthermore, mixmers, such as in table 8 and FIG. 17, but
with no thiolation, were also tested.
[0262] Antisense Activity Assay: Ha-Ras Target
[0263] It was of our interest to further evaluate the antisense
activity of oligonucleotides containing alpha-L-oxy-LNA in a gapmer
design, and compare them with beta-D-oxy-LNA gapmers.
[0264] The oligonucleotides from table 9 were prepared. We decided
to carry out the study with oligonucleotides of 16 nt in length and
a gap of 8 nt, which contain 3 residues of alpha-L-oxy-LNA in each
flank and a different extent of thiolation. 2776 is fully thiolated
(PS), while 2775 is only thiolated in the gap (PO in the flanks and
PS in the gap). The oligonucleotides were designed to target a
motif of the mRNA of Ha-Ras. Different mismatch controls were also
included, 2778 is fully thiolated and 2777 presents thiolation only
in the gap, see table 9. Moreover, the corresponding beta-D-oxy-LNA
gapmers (see table 9, 2742 is all PS, 2744 is the corresponding
mismatch control; 2743 has PS in the gap, 2745 is the corresponding
mismatch control) were also tested.
TABLE-US-00009 TABLE 9 Oligonucleotides (SEQ ID NOS 27-28, 8-9,
29-30 & 12-13, respectively, in order of appearance),
containing alpha-L-oxy-LNA and beta-D-oxy-LNA used in the antisense
activity experiments. Residue c is methyi-c both for DNA and LNA.
ref oligonucleotides 2775
T.sup.aC.sup.aC.sup.ag.sub.st.sub.sc.sub.sa.sub.st.sub.sc.sub.sg.sub.-
sc.sub.st.sub.sC.sup.aC.sup.aT.sup.ac PO/PS 2776
T.sup.a.sub.sC.sup.a.sub.sC.sup.a.sub.sg.sub.st.sub.sc.sub.sa.sub.st.-
sub.sc.sub.sg.sub.sc.sub.st.sub.sC.sup.a.sub.sC.sup.a.sub.sT.sup.a.sub.sc
All PS 2743
TCCg.sub.st.sub.sc.sub.sa.sub.st.sub.sC.sub.sg.sub.sc.sub.st.sub.sCCT-
c PO/PS 2742
T.sub.sC.sub.sC.sub.sg.sub.st.sub.sc.sub.sa.sub.st.sub.sc.sub.sg.sub.-
sc.sub.st.sub.sC.sub.sC.sub.sT.sub.sc All PS 2777
T.sup.aC.sup.aT.sup.ag.sub.st.sub.sa.sub.se.sub.st.sub.sa.sub.sg.sub.-
sc.sub.sc.sub.sC.sup.aC.sup.aC.sup.ac Mismatch control 2778
T.sup.a.sub.sC.sup.a.sub.sT.sup.a.sub.sg.sub.st.sub.sa.sub.sa.sub.st.-
sub.sa.sub.sg.sub.sc.sub.sc.sub.sC.sup.a.sub.sC.sup.a.sub.sC.sup.a.sub.sc
Mismatch control 2745
TCTg.sub.st.sub.sa.sub.sa.sub.st.sub.sa.sub.sg.sub.sC.sub.sc.sub.sCCC-
c Mismatch control 2744
T.sub.sC.sub.sT.sub.sg.sub.st.sub.sa.sub.sa.sub.st.sub.sa.sub.sg.sub.-
sC.sub.sc.sub.sC.sub.sC.sub.sC.sub.sc Mismatch control
[0265] The inclusion of alpha-L-oxy-LNA in the flanks of an
oligonucleotide results in good down-regulation levels. From FIG.
6, we can see that the oligonucleotide 2776 with alpha-L-oxy-LNA
present good antisense activity at a different range of
concentrations, 50 nM-400 nM. No significant difference in
down-regulation can be seen between 2776 and 2742. We can conclude
that the antisense activity of an oligonucleotide containing
alpha-L-oxy-LNA is at least as good as the parent beta-D-oxy-LNA
gapmer. The specificity was also tested; at 30 nM there is a
significant difference in down-regulation between the mismatch 2778
(less potent) and the match 2776. Lower concentrations (5-40 nM)
were also included from the table in FIG. 6. Potent down-regulation
is observed even at 5 nM for 2776 in comparison with the
corresponding beta-D-oxy-LNA control, 2742. The specificity is also
remarkable, if we compare the antisense activity for 2776 at 20 nM
(2.6% down-regulation) in comparison with the mismatch containing
control 2778 (77% down-regulation).
[0266] RNaseH Assay
[0267] We also evaluated gapmer designs that contain
alpha-L-oxy-LNA for their ability to recruit RNaseH activity.
[0268] alpha-L-oxy-LNA gapmer and mixmer designs recruit RnaseH
activity, see FIG. 19.
[0269] In Vivo Experiment
[0270] Nude mice were injected s.c. with MiaPaca II cells (right
flank) and 15PC3 cells (left flank) one week prior to the start of
oligonucleotide treatment to allow xenograft growth. The anti
Ha-Ras oligonucleotides (2742 and 2776, table 10) and control
oligonucleotides (2744 and 2778, table 10) were administrated for
14 days using Alzet osmotic minipumps (model 1002) implanted
dorsally. Two dosages were used: 1 and 2.5 mg/Kg/day. During
treatment the tumor growth was monitored. Tumor growth was almost
inhibited completely at 2.5 mg/Kg/day and even at 1 mg/Kg/day dose
with 2742 and 2776 in 15PC3 cells, FIG. 20. The specificity with
control oligonucleotides (2744 and 2778, containing mismatches)
increased as the dose decreased. At 1 mg/Kg/day dose the experiment
presented a good specificity, particularly for alpha-L-oxy-LNA
oligonucleotides (2742 and 2744). In MiaPacaII xenograft tumors,
the effect of the oligonucleotides is in general comparable with
those on the 15PC3 xenografts, except for the fact that the
specificity seemed to be a bit lower. It can be concluded that the
oligonucleotide containing alpha-L-oxy-LNA are as potent, or maybe
even better, as the one containing beta-D-oxy-LNA in tumor growth
inhibition in the concentration range tested.
TABLE-US-00010 TABLE 10 Oligonucleotides. (SEQ ID NOS 28, 30, 9
& 13, respectively, in order of appearance) containing
alpha-L-oxy-LNA and beta-D-oxy-LNA used in the in vivo experiments.
Residue c is methyl-c both for DNA and LNA. ref oligonucleotides
2776
T.sup.a.sub.sC.sup.a.sub.sC.sup.a.sub.sg.sub.st.sub.sc.sub.sa.sub.st.-
sub.sC.sub.sg.sub.sC.sub.st.sub.sC.sup.a.sub.sC.sup.a.sub.sT.sup.a.sub.sc
match 2778
T.sup.a.sub.sC.sup.a.sub.sT.sup.a.sub.sg.sub.st.sub.sa.sub.sa.sub.st.-
sub.sa.sub.sg.sub.sc.sub.sc.sub.sC.sup.a.sub.sC.sup.a.sub.sC.sup.a.sub.sc
Mismatch control 2742
T.sub.sC.sub.sC.sub.sg.sub.st.sub.sc.sub.sa.sub.st.sub.sc.sub.sg.sub.-
sc.sub.st.sub.sC.sub.sC.sub.sT.sub.sc match 2744
T.sub.sC.sub.sT.sub.sg.sub.st.sub.sa.sub.sa.sub.st.sub.sa.sub.sg.sub.-
sC.sub.sc.sub.sC.sub.sC.sub.sC.sub.sc Mismatch control
[0271] Toxicity Levels
[0272] The levels of aspartate aminotransferase (ASAT), alanine
aminotransferase (ALAT) and alkaline phosphatase in the serum were
determined, in order to study the possible effects of this 14-day
treatment in the nude mice. Serum samples were taken from each
mouse after the 14-day experiment. From FIG. 21, ALAT levels in the
serum varied between 250-500 U/L. ASAT levels were in the range of
80-150 U/L. The mice did not seem externally to be sick, and no big
changes in behavior were observed. During treatment the body
temperature of the mice was also monitored (FIG. 22). The body
temperature did not change significantly during the treatment, not
even at high dose 2.5 mg/Kg/day, which is an indication that no
major toxicity effects are occurring. In some cases, the body
temperature of the mice was a bit higher, divided in two groups.
These effects cannot be explained by the fact of one
oligonucleotide behaving differently or one dosage being too
high.
[0273] Specific Beta-D-Oxy-LNA Constructs
[0274] Luciferase Target: Antisense Activity Assay
[0275] Design 3-9-3-1 has a deoxynucleoside residue at the 3'-end,
see table 11 and FIG. 23. It shows significant levels of
down-regulation, in the same range than an optimised (9 nt) fully
thiolated gapmer. Moreover, only partial thiolation is needed for
these mixmers to work as good as the fully thiolated gapmer, see
FIG. 24.
TABLE-US-00011 TABLE 11 Special beta-D-oxy-LNA constructs (SEQ ID
NOS 31-33, respectively, in order of appearance) (Capital letters
for LNA and small letters for DNA). Residue c is methyl-c for LNA.
ref sequence mixmer 2023-l; 02574
TTCc.sub.sg.sub.st.sub.sc.sub.sa.sub.st.sub.sc.sub.sg.sub.st.sub.sCTTt
3-9-3-1 2023-k; 02575
TTCc.sub.sg.sub.st.sub.sc.sub.sa.sub.st.sub.sc.sub.sg.sub.st.sub.sCTT.sub-
.st 3-9-3-1 2023-j; 02576
T.sub.sT.sub.sC.sub.sc.sub.sg.sub.st.sub.sc.sub.sa.sub.st.sub.sc.sub.sg.s-
ub.st.sub.sC.sub.sT.sub.sT.sub.st 3-9-3-1
[0276] Other oligonucleotides containing novel LNA monomers
(beta-D-amino-, beta-D-thio- and alpha-L-LNA) and bearing a
deoxynucleoside residue at the 3'-end were tested in different
assays, see tables 3, 6, 9 and 10 for more detail.
Sequence CWU 1
1
33116DNAArtificial SequenceDescription of Artificial Sequence
Synthetic
oligonucleotidemodified_base(1)..(3)Beta-D-amino-LNAmisc_feature(4)..(5-
)Thiolated bondmisc_feature(5)..(6)Thiolated
bondmisc_feature(6)..(7)Thiolated bondmisc_feature(7)..(8)Thiolated
bondmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmisc_feature(12)..(13)Thiolated
bondmodified_base(13)..(15)Beta-D-amino-LNA 1tccgtcatcg ctcctc
16216DNAArtificial SequenceDescription of Artificial Sequence
Synthetic oligonucleotidemisc_feature(1)..(2)Thiolated
bondmodified_base(1)..(3)Beta-D-amino-LNAmisc_feature(2)..(3)Thiolated
bondmisc_feature(3)..(4)Thiolated bondmisc_feature(4)..(5)Thiolated
bondmisc_feature(5)..(6)Thiolated bondmisc_feature(6)..(7)Thiolated
bondmisc_feature(7)..(8)Thiolated bondmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmisc_feature(12)..(13)Thiolated
bondmisc_feature(13)..(14)Thiolated
bondmodified_base(13)..(15)Beta-D-amino-LNAmisc_feature(14)..(15)Thiolate-
d bondmisc_feature(15)..(16)Thiolated bond 2tccgtcatcg ctcctc
16316DNAArtificial SequenceDescription of Artificial Sequence
Synthetic oligonucleotidemisc_feature(1)..(2)Thiolated
bondmodified_base(1)..(3)Beta-D-oxy-LNAmisc_feature(2)..(3)Thiolated
bondmisc_feature(3)..(4)Thiolated bondmisc_feature(4)..(5)Thiolated
bondmisc_feature(5)..(6)Thiolated bondmisc_feature(6)..(7)Thiolated
bondmisc_feature(7)..(8)Thiolated bondmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmisc_feature(12)..(13)Thiolated
bondmisc_feature(13)..(14)Thiolated
bondmodified_base(13)..(15)Beta-D-oxy-LNAmisc_feature(14)..(15)Thiolated
bondmisc_feature(15)..(16)Thiolated bond 3tccgtcatcg ctcctc
16416DNAArtificial SequenceDescription of Artificial Sequence
Synthetic
oligonucleotidemodified_base(1)..(4)Beta-D-amino-LNAmisc_feature(5)..(6)T-
hiolated bondmisc_feature(6)..(7)Thiolated
bondmisc_feature(7)..(8)Thiolated bondmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmodified_base(12)..(16)Beta-D-oxy-LNA 4ttttgtcatc gtcttt
16516DNAArtificial SequenceDescription of Artificial Sequence
Synthetic
oligonucleotidemodified_base(1)..(4)Beta-D-oxy-LNAmisc_feature(5)..(6)Thi-
olated bondmisc_feature(6)..(7)Thiolated
bondmisc_feature(7)..(8)Thiolated bondmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmodified_base(12)..(16)Beta-D-oxy-LNA 5ttttgtcatc gtcttt
16616DNAArtificial SequenceDescription of Artificial Sequence
Synthetic
oligonucleotidemodified_base(1)..(3)Beta-D-amino-LNAmisc_feature(4)..(5)T-
hiolated bondmisc_feature(5)..(6)Thiolated
bondmisc_feature(6)..(7)Thiolated bondmisc_feature(7)..(8)Thiolated
bondmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmisc_feature(12)..(13)Thiolated
bondmodified_base(13)..(15)Beta-D-amino-LNA 6tccgtcatcg ctcctc
16716DNAArtificial SequenceDescription of Artificial Sequence
Synthetic oligonucleotidemisc_feature(1)..(2)Thiolated
bondmodified_base(1)..(3)Beta-D-amino-LNAmisc_feature(2)..(3)Thiolated
bondmisc_feature(3)..(4)Thiolated bondmisc_feature(4)..(5)Thiolated
bondmisc_feature(5)..(6)Thiolated bondmisc_feature(6)..(7)Thiolated
bondmisc_feature(7)..(8)Thiolated bondmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmisc_feature(12)..(13)Thiolated
bondmisc_feature(13)..(14)Thiolated
bondmodified_base(13)..(15)Beta-D-amino-LNAmisc_feature(14)..(15)Thiolate-
d bondmisc_feature(15)..(16)Thiolated bond 7tccgtcatcg ctcctc
16816DNAArtificial SequenceDescription of Artificial Sequence
Synthetic
oligonucleotidemodified_base(1)..(3)Beta-D-oxy-LNAmisc_feature(4)..(5)Thi-
olated bondmisc_feature(5)..(6)Thiolated
bondmisc_feature(6)..(7)Thiolated bondmisc_feature(7)..(8)Thiolated
bondmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmisc_feature(12)..(13)Thiolated
bondmodified_base(13)..(15)Beta-D-oxy-LNA 8tccgtcatcg ctcctc
16916DNAArtificial SequenceDescription of Artificial Sequence
Synthetic oligonucleotidemisc_feature(1)..(2)Thiolated
bondmodified_base(1)..(3)Beta-D-oxy-LNAmisc_feature(2)..(3)Thiolated
bondmisc_feature(3)..(4)Thiolated bondmisc_feature(4)..(5)Thiolated
bondmisc_feature(5)..(6)Thiolated bondmisc_feature(6)..(7)Thiolated
bondmisc_feature(7)..(8)Thiolated bondmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmisc_feature(12)..(13)Thiolated
bondmisc_feature(13)..(14)Thiolated
bondmodified_base(13)..(15)Beta-D-oxy-LNAmisc_feature(14)..(15)Thiolated
bondmisc_feature(15)..(16)Thiolated bond 9tccgtcatcg ctcctc
161016DNAArtificial SequenceDescription of Artificial Sequence
Synthetic
oligonucleotidemodified_base(1)..(3)Beta-D-amino-LNAmisc_feature(4)..(5)T-
hiolated bondmisc_feature(5)..(6)Thiolated
bondmisc_feature(6)..(7)Thiolated bondmisc_feature(7)..(8)Thiolated
bondmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmisc_feature(12)..(13)Thiolated
bondmodified_base(13)..(15)Beta-D-amino-LNA 10tctgtaatag cccccc
161116DNAArtificial SequenceDescription of Artificial Sequence
Synthetic oligonucleotidemisc_feature(1)..(2)Thiolated
bondmodified_base(1)..(3)Beta-D-amino-LNAmisc_feature(2)..(3)Thiolated
bondmisc_feature(3)..(4)Thiolated bondmisc_feature(4)..(5)Thiolated
bondmisc_feature(5)..(6)Thiolated bondmisc_feature(6)..(7)Thiolated
bondmisc_feature(7)..(8)Thiolated bondmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmisc_feature(12)..(13)Thiolated
bondmisc_feature(13)..(14)Thiolated
bondmodified_base(13)..(15)Beta-D-amino-LNAmisc_feature(14)..(15)Thiolate-
d bondmisc_feature(15)..(16)Thiolated bond 11tctgtaatag cccccc
161216DNAArtificial SequenceDescription of Artificial Sequence
Synthetic
oligonucleotidemodified_base(1)..(3)Beta-D-oxy-LNAmisc_feature(4)..(5)Thi-
olated bondmisc_feature(5)..(6)Thiolated
bondmisc_feature(6)..(7)Thiolated bondmisc_feature(7)..(8)Thiolated
bondmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmisc_feature(12)..(13)Thiolated
bondmodified_base(13)..(15)Beta-D-oxy-LNA 12tctgtaatag cccccc
161316DNAArtificial SequenceDescription of Artificial Sequence
Synthetic oligonucleotidemisc_feature(1)..(2)Thiolated
bondmodified_base(1)..(3)Beta-D-oxy-LNAmisc_feature(2)..(3)Thiolated
bondmisc_feature(3)..(4)Thiolated bondmisc_feature(4)..(5)Thiolated
bondmisc_feature(5)..(6)Thiolated bondmisc_feature(6)..(7)Thiolated
bondmisc_feature(7)..(8)Thiolated bondmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmisc_feature(12)..(13)Thiolated
bondmisc_feature(13)..(14)Thiolated
bondmodified_base(13)..(15)Beta-D-oxy-LNAmisc_feature(14)..(15)Thiolated
bondmisc_feature(15)..(16)Thiolated bond 13tctgtaatag cccccc
161416DNAArtificial SequenceDescription of Artificial Sequence
Synthetic
oligonucleotidemodified_base(1)..(3)Beta-D-thio-LNAmisc_feature(4)..(5)Th-
iolated bondmisc_feature(5)..(6)Thiolated
bondmisc_feature(6)..(7)Thiolated bondmisc_feature(7)..(8)Thiolated
bondmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmisc_feature(12)..(13)Thiolated
bondmodified_base(13)..(15)Beta-D-thio-LNA 14tccgtcatcg ctcctc
161516DNAArtificial SequenceDescription of Artificial Sequence
Synthetic oligonucleotidemisc_feature(1)..(2)Thiolated
bondmodified_base(1)..(3)Beta-D-thio-LNAmisc_feature(2)..(3)Thiolated
bondmisc_feature(3)..(4)Thiolated bondmisc_feature(4)..(5)Thiolated
bondmisc_feature(5)..(6)Thiolated bondmisc_feature(6)..(7)Thiolated
bondmisc_feature(7)..(8)Thiolated bondmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmisc_feature(12)..(13)Thiolated
bondmisc_feature(13)..(14)Thiolated
bondmodified_base(13)..(15)Beta-D-thio-LNAmisc_feature(14)..(15)Thiolated
bondmisc_feature(15)..(16)Thiolated bond 15tccgtcatcg ctcctc
161616DNAArtificial SequenceDescription of Artificial Sequence
Synthetic
oligonucleotidemodified_base(1)..(4)Beta-D-thio-LNAmisc_feature(5)..(6)Th-
iolated bondmisc_feature(6)..(7)Thiolated
bondmisc_feature(7)..(8)Thiolated bondmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmodified_base(12)..(16)Beta-D-oxy-LNA 16ttttgtcatc gtcttt
161716DNAArtificial SequenceDescription of Artificial Sequence
Synthetic
oligonucleotidemodified_base(1)..(3)Beta-D-thio-LNAmisc_feature(4)..(5)Th-
iolated bondmisc_feature(5)..(6)Thiolated
bondmisc_feature(6)..(7)Thiolated bondmisc_feature(7)..(8)Thiolated
bondmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmisc_feature(12)..(13)Thiolated
bondmodified_base(13)..(15)Beta-D-thio-LNA 17tccgtcatcg ctcctc
161816DNAArtificial SequenceDescription of Artificial Sequence
Synthetic oligonucleotidemisc_feature(1)..(2)Thiolated
bondmodified_base(1)..(3)Beta-D-thio-LNAmisc_feature(2)..(3)Thiolated
bondmisc_feature(3)..(4)Thiolated bondmisc_feature(4)..(5)Thiolated
bondmisc_feature(5)..(6)Thiolated bondmisc_feature(6)..(7)Thiolated
bondmisc_feature(7)..(8)Thiolated bondmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmisc_feature(12)..(13)Thiolated
bondmisc_feature(13)..(14)Thiolated
bondmodified_base(13)..(15)Beta-D-thio-LNAmisc_feature(14)..(15)Thiolated
bondmisc_feature(15)..(16)Thiolated bond 18tccgtcatcg ctcctc
161916DNAArtificial SequenceDescription of Artificial Sequence
Synthetic
oligonucleotidemodified_base(1)..(3)Beta-D-thio-LNAmisc_feature(4)..(5)Th-
iolated bondmisc_feature(5)..(6)Thiolated
bondmisc_feature(6)..(7)Thiolated bondmisc_feature(7)..(8)Thiolated
bondmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmisc_feature(12)..(13)Thiolated
bondmodified_base(13)..(15)Beta-D-thio-LNA 19tctgtaatag cccccc
162016DNAArtificial SequenceDescription of Artificial Sequence
Synthetic oligonucleotidemisc_feature(1)..(2)Thiolated
bondmodified_base(1)..(3)Beta-D-thio-LNAmisc_feature(2)..(3)Thiolated
bondmisc_feature(3)..(4)Thiolated bondmisc_feature(4)..(5)Thiolated
bondmisc_feature(5)..(6)Thiolated bondmisc_feature(6)..(7)Thiolated
bondmisc_feature(7)..(8)Thiolated bondmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmisc_feature(12)..(13)Thiolated
bondmisc_feature(13)..(14)Thiolated
bondmodified_base(13)..(15)Beta-D-thio-LNAmisc_feature(14)..(15)Thiolated
bondmisc_feature(15)..(16)Thiolated bond 20tctgtaatag cccccc
162116DNAArtificial SequenceDescription of Artificial Sequence
Synthetic
oligonucleotidemodified_base(1)..(3)Alpha-L-oxy-LNAmisc_feature(4)..(5)Th-
iolated bondmisc_feature(5)..(6)Thiolated
bondmisc_feature(6)..(7)Thiolated bondmisc_feature(7)..(8)Thiolated
bondmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmisc_feature(12)..(13)Thiolated
bondmodified_base(13)..(15)Alpha-L-oxy-LNA 21tccgtcatcg ctcctc
162216DNAArtificial SequenceDescription of Artificial Sequence
Synthetic oligonucleotidemisc_feature(1)..(2)Thiolated
bondmodified_base(1)..(3)Alpha-L-oxy-LNAmisc_feature(2)..(3)Thiolated
bondmisc_feature(3)..(4)Thiolated bondmisc_feature(4)..(5)Thiolated
bondmisc_feature(5)..(6)Thiolated bondmisc_feature(6)..(7)Thiolated
bondmisc_feature(7)..(8)Thiolated bondmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmisc_feature(12)..(13)Thiolated
bondmisc_feature(13)..(14)Thiolated
bondmodified_base(13)..(15)Alpha-L-oxy-LNAmisc_feature(14)..(15)Thiolated
bondmisc_feature(15)..(16)Thiolated bond 22tccgtcatcg ctcctc
162316DNAArtificial SequenceDescription of Artificial Sequence
Synthetic
oligonucleotidemodified_base(1)..(4)Beta-D-oxy-LNAmisc_feature(5)..(6)Thi-
olated
bondmodified_base(6)..(6)Alpha-L-oxy-LNAmisc_feature(6)..(7)Thiolat-
ed bondmisc_feature(7)..(8)Thiolated
bondmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmodified_base(12)..(12)Alpha-L-oxy-LNAmisc_feature(12)..(13)Thiolated
bondmisc_feature(13)..(14)Thiolated
bondmodified_base(14)..(16)Beta-D-oxy-LNA 23ttccgtcatc gtcttt
162416DNAArtificial SequenceDescription of Artificial Sequence
Synthetic
oligonucleotidemodified_base(1)..(4)Alpha-L-oxy-LNAmisc_feature(5)..(6)Th-
iolated
bondmodified_base(6)..(6)Alpha-L-oxy-LNAmisc_feature(6)..(7)Thiola-
ted bondmisc_feature(7)..(8)Thiolated
bondmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmodified_base(12)..(12)Alpha-L-oxy-LNAmisc_feature(12)..(13)Thiolated
bondmisc_feature(13)..(14)Thiolated
bondmodified_base(14)..(15)Alpha-L-oxy-LNAmodified_base(16)..(16)Beta-D-o-
xy-LNA 24ttccgtcatc gtcttt 162516DNAArtificial SequenceDescription
of Artificial Sequence Synthetic
oligonucleotidemodified_base(1)..(4)Beta-D-oxy-LNAmisc_feature(5)..(6)Thi-
olated bondmisc_feature(6)..(7)Thiolated
bondmisc_feature(7)..(8)Thiolated
bondmodified_base(8)..(8)Alpha-L-oxy-LNAmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmodified_base(12)..(16)Beta-D-oxy-LNA 25ttccgtcatc gtcttt
162616DNAArtificial
SequenceDescription of Artificial Sequence Synthetic
oligonucleotidemodified_base(1)..(3)Beta-D-oxy-LNAmodified_base(4)..(4)Al-
pha-L-oxy-LNAmisc_feature(5)..(6)Thiolated
bondmisc_feature(6)..(7)Thiolated bondmisc_feature(7)..(8)Thiolated
bondmodified_base(8)..(8)Alpha-L-oxy-LNAmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmodified_base(12)..(12)Alpha-L-oxy-LNAmodified_base(13)..(16)Beta-D-o-
xy-LNA 26ttccgtcatc gtcttt 162716DNAArtificial SequenceDescription
of Artificial Sequence Synthetic
oligonucleotidemodified_base(1)..(3)Alpha-L-oxy-LNAmisc_feature(4)..(5)Th-
iolated bondmisc_feature(5)..(6)Thiolated
bondmisc_feature(6)..(7)Thiolated bondmisc_feature(7)..(8)Thiolated
bondmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmisc_feature(12)..(13)Thiolated
bondmodified_base(13)..(15)Alpha-L-oxy-LNA 27tccgtcatcg ctcctc
162816DNAArtificial SequenceDescription of Artificial Sequence
Synthetic oligonucleotidemisc_feature(1)..(2)Thiolated
bondmodified_base(1)..(3)Alpha-L-oxy-LNAmisc_feature(2)..(3)Thiolated
bondmisc_feature(3)..(4)Thiolated bondmisc_feature(4)..(5)Thiolated
bondmisc_feature(5)..(6)Thiolated bondmisc_feature(6)..(7)Thiolated
bondmisc_feature(7)..(8)Thiolated bondmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmisc_feature(12)..(13)Thiolated
bondmisc_feature(13)..(14)Thiolated
bondmodified_base(13)..(15)Alpha-L-oxy-LNAmisc_feature(14)..(15)Thiolated
bondmisc_feature(15)..(16)Thiolated bond 28tccgtcatcg ctcctc
162916DNAArtificial SequenceDescription of Artificial Sequence
Synthetic
oligonucleotidemodified_base(1)..(3)Alpha-L-oxy-LNAmisc_feature(4)..(5)Th-
iolated bondmisc_feature(5)..(6)Thiolated
bondmisc_feature(6)..(7)Thiolated bondmisc_feature(7)..(8)Thiolated
bondmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmisc_feature(12)..(13)Thiolated
bondmodified_base(13)..(15)Alpha-L-oxy-LNA 29tctgtaatag cccccc
163016DNAArtificial SequenceDescription of Artificial Sequence
Synthetic oligonucleotidemisc_feature(1)..(2)Thiolated
bondmodified_base(1)..(3)Alpha-L-oxy-LNAmisc_feature(2)..(3)Thiolated
bondmisc_feature(3)..(4)Thiolated bondmisc_feature(4)..(5)Thiolated
bondmisc_feature(5)..(6)Thiolated bondmisc_feature(6)..(7)Thiolated
bondmisc_feature(7)..(8)Thiolated bondmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmisc_feature(12)..(13)Thiolated
bondmisc_feature(13)..(14)Thiolated
bondmodified_base(13)..(15)Alpha-L-oxy-LNAmisc_feature(14)..(15)Thiolated
bondmisc_feature(15)..(16)Thiolated bond 30tctgtaatag cccccc
163116DNAArtificial SequenceDescription of Artificial Sequence
Synthetic
oligonucleotidemodified_base(1)..(3)Beta-D-oxy-LNAmisc_feature(4)..(5)Thi-
olated bondmisc_feature(5)..(6)Thiolated
bondmisc_feature(6)..(7)Thiolated bondmisc_feature(7)..(8)Thiolated
bondmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmisc_feature(12)..(13)Thiolated
bondmodified_base(13)..(15)Beta-D-oxy-LNA 31ttccgtcatc gtcttt
163216DNAArtificial SequenceDescription of Artificial Sequence
Synthetic
oligonucleotidemodified_base(1)..(3)Beta-D-oxy-LNAmisc_feature(4)..(5)Thi-
olated bondmisc_feature(5)..(6)Thiolated
bondmisc_feature(6)..(7)Thiolated bondmisc_feature(7)..(8)Thiolated
bondmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmisc_feature(12)..(13)Thiolated
bondmodified_base(13)..(15)Beta-D-oxy-LNAmisc_feature(15)..(16)Thiolated
bond 32ttccgtcatc gtcttt 163316DNAArtificial SequenceDescription of
Artificial Sequence Synthetic
oligonucleotidemisc_feature(1)..(2)Thiolated
bondmodified_base(1)..(3)Beta-D-oxy-LNAmisc_feature(2)..(3)Thiolated
bondmisc_feature(3)..(4)Thiolated bondmisc_feature(4)..(5)Thiolated
bondmisc_feature(5)..(6)Thiolated bondmisc_feature(6)..(7)Thiolated
bondmisc_feature(7)..(8)Thiolated bondmisc_feature(8)..(9)Thiolated
bondmisc_feature(9)..(10)Thiolated
bondmisc_feature(10)..(11)Thiolated
bondmisc_feature(11)..(12)Thiolated
bondmisc_feature(12)..(13)Thiolated
bondmisc_feature(13)..(14)Thiolated
bondmodified_base(13)..(15)Beta-D-oxy-LNAmisc_feature(14)..(15)Thiolated
bondmisc_feature(15)..(16)Thiolated bond 33ttccgtcatc gtcttt 16
* * * * *